Smart74的个人主页 - 老虎社区

Smart74

Smart74

暂无个人介绍

IP属地：未知

345关注

9粉丝

0主题

0勋章

2021-10-27

Good

抱歉，原内容已删除

2021-10-16

Nice

JPMorgan On Amazon Stock: 29% Upside Potential

2021-09-11

Great and useful

抱歉，原内容已删除

2021-09-01

Good

抱歉，原内容已删除

2021-08-29

Great

Which Biotech Stock Will Shock the Market in 2022?

2021-08-17

Great

S&P 500, Dow hit record highs as defensive shares shine

2021-08-08

Great!

抱歉，原内容已删除

2021-08-04

Great!

ByteDance rival Kuaishou to end services of short video app Zynn this month

2021-07-24

Great!

抱歉，原内容已删除

2021-07-22

Useful information

抱歉，原内容已删除

2021-07-22

Nice[Smile]

Still Living in the Past, IBM Remains Behind the Tech Ball

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4087953198586960","uuid":"4087953198586960","gmtCreate":1624850135527,"gmtModify":1637027683258,"name":"Smart74","pinyin":"smart74","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/03a3700aaa7249889bedd5bd5e73f9ae","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":9,"headSize":345,"tweetSize":11,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.11","exceedPercentage":"60.41%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":855008424,"gmtCreate":1635309283667,"gmtModify":1635309283667,"author":{"id":"4087953198586960","authorId":"4087953198586960","name":"Smart74","avatar":"https://static.tigerbbs.com/03a3700aaa7249889bedd5bd5e73f9ae","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087953198586960","idStr":"4087953198586960"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/855008424","repostId":"1102311120","repostType":4,"isVote":1,"tweetType":1,"viewCount":334,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":827958512,"gmtCreate":1634395465276,"gmtModify":1634395465398,"author":{"id":"4087953198586960","authorId":"4087953198586960","name":"Smart74","avatar":"https://static.tigerbbs.com/03a3700aaa7249889bedd5bd5e73f9ae","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087953198586960","idStr":"4087953198586960"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/827958512","repostId":"1132582737","repostType":4,"repost":{"id":"1132582737","pubTimestamp":1634311475,"share":"https://www.laohu8.com/m/news/1132582737?lang=&edition=full","pubTime":"2021-10-15 23:24","market":"us","language":"en","title":"JPMorgan On Amazon Stock: 29% Upside Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=1132582737","media":"TheStreet","summary":"Amazon stock has fallen victim of its own success: shares of the e-commerce giant have lagged the S&","content":"<p>Amazon stock has fallen victim of its own success: shares of the e-commerce giant have lagged the S&amp;P 500 since its disappointing Q2 earnings day. But JPMorgan is optimistic and sees upside ahead.</p>\n<p>Since the release of Amazon’s most recent earnings report, investors have watched shares of the cloud and e-commerce giant tank by 11%. Amazon stock&nbsp;underperformed an already weak S&amp;P 500 by three percentage points over the period, leaving some to question: is AMZN still a good investment?</p>\n<p>According to experts at JPMorgan (JPM), the answer is yes. Today, the Amazon Maven presents the main reasons why five-star&nbsp;rated&nbsp;analyst Doug Anmuth believes that Amazon stock is about to surge, producing an estimated 29% in gains through 2022.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8c8e5f4ca5aa3dba7bef61858521bd17\" tg-width=\"1240\" tg-height=\"827\" width=\"100%\" height=\"auto\"><span>Figure 1: J.P. Morgan offices in Hong Kong.</span></p>\n<p><b>Getting back on track</b></p>\n<p>As the&nbsp;Amazon Maven mentioned&nbsp;recently, the impact of the pandemic on shopping habits led analysts to overestimate Amazon’s revenues for the current year. This is the very first reason why JPMorgan&nbsp;believes&nbsp;that AMZN will get a green light to climb again: “[the stock is heading] closer to the last quarter of difficult COVID-19 comps in the first quarter of 2022\", which should help to reset sentiment.</p>\n<p>Once 2020 results are left in the rearview mirror, the e-commerce company will face more realistic, non-pandemic-inflated projections. As mentioned by Mr. Anmuth himself, \"further downward revisions to 2022 profit estimates would help lower the bar and potentially create more of a clearing event”.</p>\n<p><b>Holiday upside</b></p>\n<p>Another reason why Mr. Anmuth believes Amazon stock will head higher is the beginning of the holiday season. Since the market has been so cautious towards AMZN lately, the stock has been trading at lower multiples than would otherwise be considered reasonable. The holidays, on the other hand, could be the bullish catalyst that investors need to own the stock again.</p>\n<p>Lastly, there is the potential for an increase in Prime subscription price in 2022. Considering an estimated 150 million US Prime members in 2021, a $20 dollar hike in annual fee would lead to an extra $3 billion heading towards Amazon’s coffers.</p>\n<p>At first glance, the figure may not seem like much, given Amazon’s revenues of $380 billion in 2020. However, keep in mind that nearly all the price increase would flow cleanly into Amazon’s operating income. On a 2020 basis, this would represent growth of nearly 15% in pre-tax profits.</p>\n<p><b>What do other experts say?</b></p>\n<p>Other reports published recently also support the bullish thesis. Mark Mahaney from Evercore ISI&nbsp;talked&nbsp;to 15 industry experts, including former Amazon employees, during the research firm’s Amazon Day Symposium. The analyst liked what he saw and issued a hefty $4,700 target price.</p>\n<p>Wolfe Research’s Deepak Mathivanan, on the other hand,lowered&nbsp;his price target on AMZN modestly to $3,850 from $3,900, despite maintaining an outperform rating. Sitting closer to the consensus price target is Goldman Sachs’ Eric Sheridan, who is bullish and&nbsp;believes&nbsp;that AMZN shares are worth $4,250.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JPMorgan On Amazon Stock: 29% Upside Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJPMorgan On Amazon Stock: 29% Upside Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-15 23:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/amazon/news/jpmorgan-on-amazon-stock-29-upside-potential><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Amazon stock has fallen victim of its own success: shares of the e-commerce giant have lagged the S&P 500 since its disappointing Q2 earnings day. But JPMorgan is optimistic and sees upside ahead.\n...</p>\n\n<a href=\"https://www.thestreet.com/amazon/news/jpmorgan-on-amazon-stock-29-upside-potential\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊"},"source_url":"https://www.thestreet.com/amazon/news/jpmorgan-on-amazon-stock-29-upside-potential","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1132582737","content_text":"Amazon stock has fallen victim of its own success: shares of the e-commerce giant have lagged the S&P 500 since its disappointing Q2 earnings day. But JPMorgan is optimistic and sees upside ahead.\nSince the release of Amazon’s most recent earnings report, investors have watched shares of the cloud and e-commerce giant tank by 11%. Amazon stock underperformed an already weak S&P 500 by three percentage points over the period, leaving some to question: is AMZN still a good investment?\nAccording to experts at JPMorgan (JPM), the answer is yes. Today, the Amazon Maven presents the main reasons why five-star rated analyst Doug Anmuth believes that Amazon stock is about to surge, producing an estimated 29% in gains through 2022.\nFigure 1: J.P. Morgan offices in Hong Kong.\nGetting back on track\nAs the Amazon Maven mentioned recently, the impact of the pandemic on shopping habits led analysts to overestimate Amazon’s revenues for the current year. This is the very first reason why JPMorgan believes that AMZN will get a green light to climb again: “[the stock is heading] closer to the last quarter of difficult COVID-19 comps in the first quarter of 2022\", which should help to reset sentiment.\nOnce 2020 results are left in the rearview mirror, the e-commerce company will face more realistic, non-pandemic-inflated projections. As mentioned by Mr. Anmuth himself, \"further downward revisions to 2022 profit estimates would help lower the bar and potentially create more of a clearing event”.\nHoliday upside\nAnother reason why Mr. Anmuth believes Amazon stock will head higher is the beginning of the holiday season. Since the market has been so cautious towards AMZN lately, the stock has been trading at lower multiples than would otherwise be considered reasonable. The holidays, on the other hand, could be the bullish catalyst that investors need to own the stock again.\nLastly, there is the potential for an increase in Prime subscription price in 2022. Considering an estimated 150 million US Prime members in 2021, a $20 dollar hike in annual fee would lead to an extra $3 billion heading towards Amazon’s coffers.\nAt first glance, the figure may not seem like much, given Amazon’s revenues of $380 billion in 2020. However, keep in mind that nearly all the price increase would flow cleanly into Amazon’s operating income. On a 2020 basis, this would represent growth of nearly 15% in pre-tax profits.\nWhat do other experts say?\nOther reports published recently also support the bullish thesis. Mark Mahaney from Evercore ISI talked to 15 industry experts, including former Amazon employees, during the research firm’s Amazon Day Symposium. The analyst liked what he saw and issued a hefty $4,700 target price.\nWolfe Research’s Deepak Mathivanan, on the other hand,lowered his price target on AMZN modestly to $3,850 from $3,900, despite maintaining an outperform rating. Sitting closer to the consensus price target is Goldman Sachs’ Eric Sheridan, who is bullish and believes that AMZN shares are worth $4,250.","news_type":1},"isVote":1,"tweetType":1,"viewCount":528,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":881541834,"gmtCreate":1631369712128,"gmtModify":1632882920567,"author":{"id":"4087953198586960","authorId":"4087953198586960","name":"Smart74","avatar":"https://static.tigerbbs.com/03a3700aaa7249889bedd5bd5e73f9ae","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087953198586960","idStr":"4087953198586960"},"themes":[],"htmlText":"Great and useful","listText":"Great and useful","text":"Great and useful","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/881541834","repostId":"2166376256","repostType":4,"isVote":1,"tweetType":1,"viewCount":101,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":816936916,"gmtCreate":1630459575735,"gmtModify":1633677911946,"author":{"id":"4087953198586960","authorId":"4087953198586960","name":"Smart74","avatar":"https://static.tigerbbs.com/03a3700aaa7249889bedd5bd5e73f9ae","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087953198586960","idStr":"4087953198586960"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/816936916","repostId":"1116780264","repostType":4,"isVote":1,"tweetType":1,"viewCount":209,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":813506813,"gmtCreate":1630210115732,"gmtModify":1704957088579,"author":{"id":"4087953198586960","authorId":"4087953198586960","name":"Smart74","avatar":"https://static.tigerbbs.com/03a3700aaa7249889bedd5bd5e73f9ae","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087953198586960","idStr":"4087953198586960"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/813506813","repostId":"2162602132","repostType":4,"repost":{"id":"2162602132","pubTimestamp":1630076857,"share":"https://www.laohu8.com/m/news/2162602132?lang=&edition=full","pubTime":"2021-08-27 23:07","market":"us","language":"en","title":"Which Biotech Stock Will Shock the Market in 2022?","url":"https://stock-news.laohu8.com/highlight/detail?id=2162602132","media":"Motley Fool","summary":"Over the last few years, three tiny biotechs emerged out of nowhere to give amazing returns to early investors. Which biotech might pull off a similar feat in 2022?","content":"<p>In 2019, tiny&nbsp;<b><a href=\"https://laohu8.com/S/AXSM\">Axsome Therapeutics</a>&nbsp;</b>(NASDAQ:AXSM) emerged from micro-cap obscurity to become the best-performing stock in the market, rising by an amazing 3,600% in a year. In 2020, another tiny biotech,&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;</b>(NASDAQ:NVAX), came out of nowhere to stomp the stock market, with its share price skyrocketing by 2,700%. For most of 2021, yet another small biotech has been the top-performing stock in the market, as&nbsp;<b><a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a> </b>(NASDAQ:SAVA) jumped from under $7 a share in January to $123 a share on Aug. 24. (Whether it will keep its lead is another question, as the volatility is savage -- the stock is down to $52 as of Friday morning after news of a citizen petition against the company.)</p>\n<p>What's fascinating about the biotech sector in particular is how fast it moves. The sector is notorious for amazing price swings -- in either direction -- that can happen overnight. So why is that? Why are biotech stocks in particular so volatile? Why do they keep leading the market every year? And what biotech stock might -- repeat, <i>might&nbsp;</i>-- pull off this feat next year? Let's analyze why Axsome, Novavax, and Cassava zoomed higher over the last few years, and why I think <b><a href=\"https://laohu8.com/S/PIRS\">Pieris Pharmaceuticals</a> </b>(NASDAQ:PIRS) has a chance at a similar remarkable performance in 2022.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F638648%2Fgettyimages-108224060.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"465\" referrerpolicy=\"no-referrer\"></p>\n<h2>Biotech winners tend to start off tiny</h2>\n<p>The main reason these stocks were able to soar so impressively is that all three started with very tiny market caps. At the end of 2018, Axsome Therapeutics had a micro-cap valuation of $85 million. In 2019, Novavax stock fell to below $1, and the company had to do a 1-for-20 reverse split in order to keep its shares listed on the <b><a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a></b>. And at the beginning of 2020, Cassava had barely achieved small-cap status, with its market cap hovering at $240 million.</p>\n<p>So all three barn-burning stocks started off unloved by the market. Why does a biotech stock get so cheap? Probably the most common reason is the market believes the company's science is bad. Novavax, for instance, had a notable failure in its quest for a respiratory syncytial virus (RSV) vaccine. This clinical trial failure sent investors to the exits and sent the stock down into a crater in 2019, when it plunged to $4 a share (or $0.20 pre-split).</p>\n<p>Yet the market was spectacularly wrong about Novavax. While the company's RSV drug was a failure, Novavax had another drug in clinical trials, a flu vaccine. And this drug was a world-beater. It was flying through clinical trials, and it had defeated the market-leading flu vaccines from <b><a href=\"https://laohu8.com/S/SNY\">Sanofi SA</a></b>&nbsp;(NASDAQ:SNY) over and over again.</p>\n<p>In 2019, Novavax had the label of \"bad science,\" but the data for a different drug said otherwise. Sometimes companies with tiny market caps actually have compelling drugs that are performing exceptionally well in clinical trials. If you find such a company, you might want to buy some shares.</p>\n<h2>Is there enough money for a phase 3 trial?</h2>\n<p>That said, it's not enough just to have good science. Nobody is allowed to market their drugs to the public until that science has been validated in clinical trials and approved by the U.S. Food and Drug Administration -- and clinical trials cost a huge amount of money. Thus, before investing, it's important to determine whether the biotech has enough cash for a phase 3 trial. If the answer is \"no,\" the drug is stalled and won't go anywhere.</p>\n<p>Many unprofitable biotech companies finesse the money issue by collaborating with Big Pharma. When you see such a collaboration, you can have faith that there's enough cash for a phase 3 trial. However, these arrangements also often mean that the bigger pharmaceutical company acquires the rights to the molecule. And that can be like like selling off your future in order to pay the bills today.</p>\n<p>Interestingly, neither Axsome nor Novavax nor Cassava have an active collaboration with any big-pharma leaders. Instead, all three of these companies have elected to own 100% of the rights to their lead molecules. While the median expense for a phase 3 trial is $19 million, the numbers can vary dramatically, depending on how large the patient population is. I'd be nervous if a biotech had less than $100 million in cash (each of these has more). There's no question this independent approach is riskier, but also potentially a lot more rewarding.</p>\n<p>Biotech investors often like to see collaboration with Big Pharma -- it's a validation of the science, and it removes a lot of financial worries for small companies. But if you're chasing big rewards, you might want to look at biotech companies that are still independent (and have enough cash to stay that way).</p>\n<h2>Can Pieris pull off a miracle run in 2022?</h2>\n<p>Pieris stock is very cheap right now, with a $291 million valuation. (You know a stock is cheap when it could have a 10-bagger and still qualify as a small-cap!) Is the stock so cheap because its science is bad?</p>\n<p>It would probably be more accurate to say that Pieris' science is unproven. Like many unprofitable biotechs, Pieris doesn't have a drug in phase 3 trials yet. In fact, we're still waiting on positive phase 2 data. So it's early, and that's a danger sign. The reason Axsome, Novavax, and Cassava all skyrocketed is that all three companies made the journey from unproven drug to pivotal trials very quickly. Pieris is a few years away.</p>\n<p>Another major difference is that Pieris has signed multiple collaborative deals -- with <b>Roche</b>, <b>AstraZeneca</b>, and <b>Seagen</b>, among others. In <a href=\"https://laohu8.com/S/AONE.U\">one</a> sense that's good news, because it means that money for clinical trials isn't an issue for the company. Any drugs that work will make it to phase 3 trials and beyond. And all this collaboration adds confidence that the company is on the right track.</p>\n<p>Is Pieris sacrificing its future to pay for its present? In my opinion, no. While AstraZeneca now has rights to the company's asthma drug (its lead molecule), what makes Pieris such an exciting stock is not <a href=\"https://laohu8.com/S/AONE.U\">one</a> particular drug, but the company's entire platform. Pieris owns the rights to all the Anticalin proteins, and its library contains more than 100 billion of these new molecules. Anticalins are much smaller than antibodies, and as such can go where antibodies cannot. AstraZeneca paid big bucks for the rights to Pieris' asthma drug because that Anticalin molecule is small enough to go directly to the lung.</p>\n<p>I love the risk/reward equation for Pieris. If the company's drugs actually work -- we'll have data in that regard next year -- the stock will shoot much higher. Under its existing collaboration agreements, Pieris might make up to $9 billion if its Anticalin drugs reach certain milestones.&nbsp;But what will really make the stock take off is if/when other pharmaceutical players start making deals to add some of the company's Anticalin molecules to their pipelines.</p>\n<p>How do you value an entire new class of pharmaceuticals? Well, in 2019, worldwide sales for monoclonal antibodies (mAbs) totaled <i>$163 billion</i>. If Pieris' partners report any positive data on its Anticalin drugs next year, the upside for this stock is enormous.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Which Biotech Stock Will Shock the Market in 2022?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhich Biotech Stock Will Shock the Market in 2022?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-27 23:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/27/which-biotech-stock-will-shock-the-market-in-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In 2019, tiny Axsome Therapeutics (NASDAQ:AXSM) emerged from micro-cap obscurity to become the best-performing stock in the market, rising by an amazing 3,600% in a year. In 2020, another tiny biotech...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/27/which-biotech-stock-will-shock-the-market-in-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PIRS":"Pieris Pharmaceuticals, Inc.","SAVA":"Cassava Sciences Inc","AXSM":"Axsome Therapeutics, Inc.","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/27/which-biotech-stock-will-shock-the-market-in-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2162602132","content_text":"In 2019, tiny Axsome Therapeutics (NASDAQ:AXSM) emerged from micro-cap obscurity to become the best-performing stock in the market, rising by an amazing 3,600% in a year. In 2020, another tiny biotech, Novavax (NASDAQ:NVAX), came out of nowhere to stomp the stock market, with its share price skyrocketing by 2,700%. For most of 2021, yet another small biotech has been the top-performing stock in the market, as Cassava Sciences Inc (NASDAQ:SAVA) jumped from under $7 a share in January to $123 a share on Aug. 24. (Whether it will keep its lead is another question, as the volatility is savage -- the stock is down to $52 as of Friday morning after news of a citizen petition against the company.)\nWhat's fascinating about the biotech sector in particular is how fast it moves. The sector is notorious for amazing price swings -- in either direction -- that can happen overnight. So why is that? Why are biotech stocks in particular so volatile? Why do they keep leading the market every year? And what biotech stock might -- repeat, might -- pull off this feat next year? Let's analyze why Axsome, Novavax, and Cassava zoomed higher over the last few years, and why I think Pieris Pharmaceuticals (NASDAQ:PIRS) has a chance at a similar remarkable performance in 2022.\n\nBiotech winners tend to start off tiny\nThe main reason these stocks were able to soar so impressively is that all three started with very tiny market caps. At the end of 2018, Axsome Therapeutics had a micro-cap valuation of $85 million. In 2019, Novavax stock fell to below $1, and the company had to do a 1-for-20 reverse split in order to keep its shares listed on the Nasdaq. And at the beginning of 2020, Cassava had barely achieved small-cap status, with its market cap hovering at $240 million.\nSo all three barn-burning stocks started off unloved by the market. Why does a biotech stock get so cheap? Probably the most common reason is the market believes the company's science is bad. Novavax, for instance, had a notable failure in its quest for a respiratory syncytial virus (RSV) vaccine. This clinical trial failure sent investors to the exits and sent the stock down into a crater in 2019, when it plunged to $4 a share (or $0.20 pre-split).\nYet the market was spectacularly wrong about Novavax. While the company's RSV drug was a failure, Novavax had another drug in clinical trials, a flu vaccine. And this drug was a world-beater. It was flying through clinical trials, and it had defeated the market-leading flu vaccines from Sanofi SA (NASDAQ:SNY) over and over again.\nIn 2019, Novavax had the label of \"bad science,\" but the data for a different drug said otherwise. Sometimes companies with tiny market caps actually have compelling drugs that are performing exceptionally well in clinical trials. If you find such a company, you might want to buy some shares.\nIs there enough money for a phase 3 trial?\nThat said, it's not enough just to have good science. Nobody is allowed to market their drugs to the public until that science has been validated in clinical trials and approved by the U.S. Food and Drug Administration -- and clinical trials cost a huge amount of money. Thus, before investing, it's important to determine whether the biotech has enough cash for a phase 3 trial. If the answer is \"no,\" the drug is stalled and won't go anywhere.\nMany unprofitable biotech companies finesse the money issue by collaborating with Big Pharma. When you see such a collaboration, you can have faith that there's enough cash for a phase 3 trial. However, these arrangements also often mean that the bigger pharmaceutical company acquires the rights to the molecule. And that can be like like selling off your future in order to pay the bills today.\nInterestingly, neither Axsome nor Novavax nor Cassava have an active collaboration with any big-pharma leaders. Instead, all three of these companies have elected to own 100% of the rights to their lead molecules. While the median expense for a phase 3 trial is $19 million, the numbers can vary dramatically, depending on how large the patient population is. I'd be nervous if a biotech had less than $100 million in cash (each of these has more). There's no question this independent approach is riskier, but also potentially a lot more rewarding.\nBiotech investors often like to see collaboration with Big Pharma -- it's a validation of the science, and it removes a lot of financial worries for small companies. But if you're chasing big rewards, you might want to look at biotech companies that are still independent (and have enough cash to stay that way).\nCan Pieris pull off a miracle run in 2022?\nPieris stock is very cheap right now, with a $291 million valuation. (You know a stock is cheap when it could have a 10-bagger and still qualify as a small-cap!) Is the stock so cheap because its science is bad?\nIt would probably be more accurate to say that Pieris' science is unproven. Like many unprofitable biotechs, Pieris doesn't have a drug in phase 3 trials yet. In fact, we're still waiting on positive phase 2 data. So it's early, and that's a danger sign. The reason Axsome, Novavax, and Cassava all skyrocketed is that all three companies made the journey from unproven drug to pivotal trials very quickly. Pieris is a few years away.\nAnother major difference is that Pieris has signed multiple collaborative deals -- with Roche, AstraZeneca, and Seagen, among others. In one sense that's good news, because it means that money for clinical trials isn't an issue for the company. Any drugs that work will make it to phase 3 trials and beyond. And all this collaboration adds confidence that the company is on the right track.\nIs Pieris sacrificing its future to pay for its present? In my opinion, no. While AstraZeneca now has rights to the company's asthma drug (its lead molecule), what makes Pieris such an exciting stock is not one particular drug, but the company's entire platform. Pieris owns the rights to all the Anticalin proteins, and its library contains more than 100 billion of these new molecules. Anticalins are much smaller than antibodies, and as such can go where antibodies cannot. AstraZeneca paid big bucks for the rights to Pieris' asthma drug because that Anticalin molecule is small enough to go directly to the lung.\nI love the risk/reward equation for Pieris. If the company's drugs actually work -- we'll have data in that regard next year -- the stock will shoot much higher. Under its existing collaboration agreements, Pieris might make up to $9 billion if its Anticalin drugs reach certain milestones. But what will really make the stock take off is if/when other pharmaceutical players start making deals to add some of the company's Anticalin molecules to their pipelines.\nHow do you value an entire new class of pharmaceuticals? Well, in 2019, worldwide sales for monoclonal antibodies (mAbs) totaled $163 billion. If Pieris' partners report any positive data on its Anticalin drugs next year, the upside for this stock is enormous.","news_type":1},"isVote":1,"tweetType":1,"viewCount":101,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":839252931,"gmtCreate":1629163033923,"gmtModify":1633686922842,"author":{"id":"4087953198586960","authorId":"4087953198586960","name":"Smart74","avatar":"https://static.tigerbbs.com/03a3700aaa7249889bedd5bd5e73f9ae","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087953198586960","idStr":"4087953198586960"},"themes":[],"htmlText":"Great&nbsp;","listText":"Great&nbsp;","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/839252931","repostId":"2160278866","repostType":4,"repost":{"id":"2160278866","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1629153526,"share":"https://www.laohu8.com/m/news/2160278866?lang=&edition=full","pubTime":"2021-08-17 06:38","market":"us","language":"en","title":"S&P 500, Dow hit record highs as defensive shares shine","url":"https://stock-news.laohu8.com/highlight/detail?id=2160278866","media":"Reuters","summary":"* Healthcare sector rises over 1%, utilities, staples gain\n* Cyclical areas off: Energy, materials, ","content":"<p>* Healthcare sector rises over 1%, utilities, staples gain</p>\n<p>* Cyclical areas off: Energy, materials, financials weak</p>\n<p>* China factory output, retail sales growth slow sharply</p>\n<p>* Tesla slumps after U.S. opens probe into Autopilot</p>\n<p>* Dow up 0.31%, S&amp;P up 0.26%, Nasdaq down 0.2%</p>\n<p>Aug 16 (Reuters) - The benchmark S&amp;P 500 and the Dow industrials hit record highs on Monday as investors moved into defensive sectors and stocks recovered from losses earlier in the session, shaking off glum economic data out of China.</p>\n<p>Economically sensitive groups such as energy, materials and financials were weaker after China's factory output and retail sales growth slowed sharply and missed expectations in July, as new COVID-19 outbreaks and floods disrupted business operations.</p>\n<p>But healthcare gained 1.1%, the best-performing S&amp;P 500 sector. Utilities and consumer staples -- also generally regarded as defensive sectors -- further bolstered market gains.</p>\n<p>The S&amp;P 500 and the Dow both posted record high closes for their fifth straight sessions, even after the major indexes were initially well in the red.</p>\n<p>\"There is just huge amounts of liquidity, massive amounts of cash out there, both on corporate balance sheets and in private investors’ pockets, and because of that every tiny dip that there is, people look for bargains and they buy and they keep it buoyant,\" said Randy Frederick, vice president of trading and derivatives for Charles Schwab in Austin, Texas.</p>\n<p>The Dow Jones Industrial Average rose 110.02 points, or 0.31%, to 35,625.4, the S&amp;P 500 gained 11.71 points, or 0.26%, to 4,479.71 and the Nasdaq Composite dropped 29.14 points, or 0.2%, to 14,793.76.</p>\n<p>A rebound in the U.S. economy including a stellar second-quarter corporate earnings season along with accommodative monetary policy has underpinned positive sentiment for equities. The S&amp;P 500 has gained 100% since its March 2020 low.</p>\n<p>“The overall environment remains supportive of risk assets, so there is a gravitational pull upward for stocks,” said Kristina Hooper, chief global market strategist at Invesco.</p>\n<p>Investors are looking for signs about when the Federal Reserve will rein in its easy money policies, with minutes from the central bank's latest meeting due on Wednesday. A resurgence in COVID-19 cases and the impact on the economy are keeping markets on edge, with investors watching earnings reports from major retailers due later in the week.</p>\n<p>Investors were also digesting news from Afghanistan, where thousands of civilians desperate to flee the country thronged Kabul airport after the Taliban seized the capital.</p>\n<p>In company news, Tesla shares fell 4.3% after U.S. auto safety regulators said they had opened a formal safety probe into the company's driver assistance system Autopilot after a series of crashes involving emergency vehicles.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.75-to-1 ratio; on Nasdaq, a 2.22-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 68 new 52-week highs and one new lows; the Nasdaq Composite recorded 72 new highs and 259 new lows.</p>\n<p>About 8.5 billion shares changed hands in U.S. exchanges, below the 9.2 billion daily average over the last 20 sessions.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 500, Dow hit record highs as defensive shares shine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500, Dow hit record highs as defensive shares shine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-17 06:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>* Healthcare sector rises over 1%, utilities, staples gain</p>\n<p>* Cyclical areas off: Energy, materials, financials weak</p>\n<p>* China factory output, retail sales growth slow sharply</p>\n<p>* Tesla slumps after U.S. opens probe into Autopilot</p>\n<p>* Dow up 0.31%, S&amp;P up 0.26%, Nasdaq down 0.2%</p>\n<p>Aug 16 (Reuters) - The benchmark S&amp;P 500 and the Dow industrials hit record highs on Monday as investors moved into defensive sectors and stocks recovered from losses earlier in the session, shaking off glum economic data out of China.</p>\n<p>Economically sensitive groups such as energy, materials and financials were weaker after China's factory output and retail sales growth slowed sharply and missed expectations in July, as new COVID-19 outbreaks and floods disrupted business operations.</p>\n<p>But healthcare gained 1.1%, the best-performing S&amp;P 500 sector. Utilities and consumer staples -- also generally regarded as defensive sectors -- further bolstered market gains.</p>\n<p>The S&amp;P 500 and the Dow both posted record high closes for their fifth straight sessions, even after the major indexes were initially well in the red.</p>\n<p>\"There is just huge amounts of liquidity, massive amounts of cash out there, both on corporate balance sheets and in private investors’ pockets, and because of that every tiny dip that there is, people look for bargains and they buy and they keep it buoyant,\" said Randy Frederick, vice president of trading and derivatives for Charles Schwab in Austin, Texas.</p>\n<p>The Dow Jones Industrial Average rose 110.02 points, or 0.31%, to 35,625.4, the S&amp;P 500 gained 11.71 points, or 0.26%, to 4,479.71 and the Nasdaq Composite dropped 29.14 points, or 0.2%, to 14,793.76.</p>\n<p>A rebound in the U.S. economy including a stellar second-quarter corporate earnings season along with accommodative monetary policy has underpinned positive sentiment for equities. The S&amp;P 500 has gained 100% since its March 2020 low.</p>\n<p>“The overall environment remains supportive of risk assets, so there is a gravitational pull upward for stocks,” said Kristina Hooper, chief global market strategist at Invesco.</p>\n<p>Investors are looking for signs about when the Federal Reserve will rein in its easy money policies, with minutes from the central bank's latest meeting due on Wednesday. A resurgence in COVID-19 cases and the impact on the economy are keeping markets on edge, with investors watching earnings reports from major retailers due later in the week.</p>\n<p>Investors were also digesting news from Afghanistan, where thousands of civilians desperate to flee the country thronged Kabul airport after the Taliban seized the capital.</p>\n<p>In company news, Tesla shares fell 4.3% after U.S. auto safety regulators said they had opened a formal safety probe into the company's driver assistance system Autopilot after a series of crashes involving emergency vehicles.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.75-to-1 ratio; on Nasdaq, a 2.22-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 68 new 52-week highs and one new lows; the Nasdaq Composite recorded 72 new highs and 259 new lows.</p>\n<p>About 8.5 billion shares changed hands in U.S. exchanges, below the 9.2 billion daily average over the last 20 sessions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF",".IXIC":"NASDAQ Composite","SH":"标普500反向ETF","IVV":"标普500指数ETF","TSLA":"特斯拉",".DJI":"道琼斯","SPY":"标普500ETF","UPRO":"三倍做多标普500ETF","OEX":"标普100",".SPX":"S&P 500 Index","SPXU":"三倍做空标普500ETF","SDS":"两倍做空标普500ETF","OEF":"标普100指数ETF-iShares","SSO":"两倍做多标普500ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2160278866","content_text":"* Healthcare sector rises over 1%, utilities, staples gain\n* Cyclical areas off: Energy, materials, financials weak\n* China factory output, retail sales growth slow sharply\n* Tesla slumps after U.S. opens probe into Autopilot\n* Dow up 0.31%, S&P up 0.26%, Nasdaq down 0.2%\nAug 16 (Reuters) - The benchmark S&P 500 and the Dow industrials hit record highs on Monday as investors moved into defensive sectors and stocks recovered from losses earlier in the session, shaking off glum economic data out of China.\nEconomically sensitive groups such as energy, materials and financials were weaker after China's factory output and retail sales growth slowed sharply and missed expectations in July, as new COVID-19 outbreaks and floods disrupted business operations.\nBut healthcare gained 1.1%, the best-performing S&P 500 sector. Utilities and consumer staples -- also generally regarded as defensive sectors -- further bolstered market gains.\nThe S&P 500 and the Dow both posted record high closes for their fifth straight sessions, even after the major indexes were initially well in the red.\n\"There is just huge amounts of liquidity, massive amounts of cash out there, both on corporate balance sheets and in private investors’ pockets, and because of that every tiny dip that there is, people look for bargains and they buy and they keep it buoyant,\" said Randy Frederick, vice president of trading and derivatives for Charles Schwab in Austin, Texas.\nThe Dow Jones Industrial Average rose 110.02 points, or 0.31%, to 35,625.4, the S&P 500 gained 11.71 points, or 0.26%, to 4,479.71 and the Nasdaq Composite dropped 29.14 points, or 0.2%, to 14,793.76.\nA rebound in the U.S. economy including a stellar second-quarter corporate earnings season along with accommodative monetary policy has underpinned positive sentiment for equities. The S&P 500 has gained 100% since its March 2020 low.\n“The overall environment remains supportive of risk assets, so there is a gravitational pull upward for stocks,” said Kristina Hooper, chief global market strategist at Invesco.\nInvestors are looking for signs about when the Federal Reserve will rein in its easy money policies, with minutes from the central bank's latest meeting due on Wednesday. A resurgence in COVID-19 cases and the impact on the economy are keeping markets on edge, with investors watching earnings reports from major retailers due later in the week.\nInvestors were also digesting news from Afghanistan, where thousands of civilians desperate to flee the country thronged Kabul airport after the Taliban seized the capital.\nIn company news, Tesla shares fell 4.3% after U.S. auto safety regulators said they had opened a formal safety probe into the company's driver assistance system Autopilot after a series of crashes involving emergency vehicles.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.75-to-1 ratio; on Nasdaq, a 2.22-to-1 ratio favored decliners.\nThe S&P 500 posted 68 new 52-week highs and one new lows; the Nasdaq Composite recorded 72 new highs and 259 new lows.\nAbout 8.5 billion shares changed hands in U.S. exchanges, below the 9.2 billion daily average over the last 20 sessions.","news_type":1},"isVote":1,"tweetType":1,"viewCount":161,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":891577728,"gmtCreate":1628405644664,"gmtModify":1633747296274,"author":{"id":"4087953198586960","authorId":"4087953198586960","name":"Smart74","avatar":"https://static.tigerbbs.com/03a3700aaa7249889bedd5bd5e73f9ae","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087953198586960","idStr":"4087953198586960"},"themes":[],"htmlText":"Great!","listText":"Great!","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/891577728","repostId":"1190347839","repostType":4,"isVote":1,"tweetType":1,"viewCount":158,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":807778566,"gmtCreate":1628063364355,"gmtModify":1633753932437,"author":{"id":"4087953198586960","authorId":"4087953198586960","name":"Smart74","avatar":"https://static.tigerbbs.com/03a3700aaa7249889bedd5bd5e73f9ae","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087953198586960","idStr":"4087953198586960"},"themes":[],"htmlText":"Great!","listText":"Great!","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/807778566","repostId":"2156174967","repostType":4,"repost":{"id":"2156174967","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1628060758,"share":"https://www.laohu8.com/m/news/2156174967?lang=&edition=full","pubTime":"2021-08-04 15:05","market":"hk","language":"en","title":"ByteDance rival Kuaishou to end services of short video app Zynn this month","url":"https://stock-news.laohu8.com/highlight/detail?id=2156174967","media":"Reuters","summary":"BEIJING, Aug 4 (Reuters) - ByteDance rival Kuaishou Technology said on Wednesday it would stop servi","content":"<p>BEIJING, Aug 4 (Reuters) - ByteDance rival Kuaishou Technology said on Wednesday it would stop services of its short video app Zynn on Aug. 20.</p>\n<p>The termination of Zynn is part of its normal operations, and the company's other products for markets outside China will not be affected, Kuaishou said in a statement.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ByteDance rival Kuaishou to end services of short video app Zynn this month</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nByteDance rival Kuaishou to end services of short video app Zynn this month\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-04 15:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BEIJING, Aug 4 (Reuters) - ByteDance rival Kuaishou Technology said on Wednesday it would stop services of its short video app Zynn on Aug. 20.</p>\n<p>The termination of Zynn is part of its normal operations, and the company's other products for markets outside China will not be affected, Kuaishou said in a statement.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"01024":"快手-W"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156174967","content_text":"BEIJING, Aug 4 (Reuters) - ByteDance rival Kuaishou Technology said on Wednesday it would stop services of its short video app Zynn on Aug. 20.\nThe termination of Zynn is part of its normal operations, and the company's other products for markets outside China will not be affected, Kuaishou said in a statement.","news_type":1},"isVote":1,"tweetType":1,"viewCount":179,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":174233558,"gmtCreate":1627099846574,"gmtModify":1633767953220,"author":{"id":"4087953198586960","authorId":"4087953198586960","name":"Smart74","avatar":"https://static.tigerbbs.com/03a3700aaa7249889bedd5bd5e73f9ae","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087953198586960","idStr":"4087953198586960"},"themes":[],"htmlText":"Great!","listText":"Great!","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/174233558","repostId":"2153751984","repostType":4,"isVote":1,"tweetType":1,"viewCount":87,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172227920,"gmtCreate":1626963420260,"gmtModify":1633769319400,"author":{"id":"4087953198586960","authorId":"4087953198586960","name":"Smart74","avatar":"https://static.tigerbbs.com/03a3700aaa7249889bedd5bd5e73f9ae","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087953198586960","idStr":"4087953198586960"},"themes":[],"htmlText":"Useful information&nbsp;","listText":"Useful information&nbsp;","text":"Useful information","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/172227920","repostId":"2153711620","repostType":4,"isVote":1,"tweetType":1,"viewCount":129,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172220717,"gmtCreate":1626963127439,"gmtModify":1633769323601,"author":{"id":"4087953198586960","authorId":"4087953198586960","name":"Smart74","avatar":"https://static.tigerbbs.com/03a3700aaa7249889bedd5bd5e73f9ae","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087953198586960","idStr":"4087953198586960"},"themes":[],"htmlText":"Nice[Smile]&nbsp;","listText":"Nice[Smile]&nbsp;","text":"Nice[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/172220717","repostId":"1175975559","repostType":4,"repost":{"id":"1175975559","pubTimestamp":1626958493,"share":"https://www.laohu8.com/m/news/1175975559?lang=&edition=full","pubTime":"2021-07-22 20:54","market":"us","language":"en","title":"Still Living in the Past, IBM Remains Behind the Tech Ball","url":"https://stock-news.laohu8.com/highlight/detail?id=1175975559","media":"InvestorPlace","summary":"IBM hasn't had any wins in a quarter century -- and it's not about to start. Here's what's behind IB","content":"<blockquote>\n <a href=\"https://laohu8.com/S/IBM\">IBM</a> hasn't had any wins in a quarter century -- and it's not about to start. Here's what's behind IBM stock.\n</blockquote>\n<p>To make a comparison to football,&nbsp;<b><a href=\"https://laohu8.com/S/IBM\">IBM</a> </b>is the Dallas Cowboys of technology. How do I mean? Well, both IBM and the Cowboys are overrated. They haven’t won a title in a quarter century and they’re not going to do it this year. Their system is stale, yet somehow they still have fans. All around, IBM stock represents a disappointment.</p>\n<p><img src=\"https://static.tigerbbs.com/23c40f297776e475ef48e891e3c26f52\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: shutterstock.com/LCV</p>\n<p>Basically, both the Cowboys and IBM are living in the past. The Cowboys revere football icon Tom Landry while actually being run by Jerry Jones. Similarly, IBM still reveres its 20th century leaders while still feeling the effects of former CEO and current executive chairmanVirginia Rometty.</p>\n<p>This much became clear when Jim Whitehurst, who brought IBM a new cachet with <a href=\"https://laohu8.com/S/RHT\">Red Hat</a> in 2019,announced his departure. Rometty and the IBM bureaucracy outmaneuvered him, installing Arvind Krishna as CEO. Now, the company is still behind the ball.</p>\n<p><b>IBM Stock: Rometty’s Bad Plays</b></p>\n<p>Rometty — who became CEO in 2012 after a career in marketing — compiled <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the worst executive records of the last decade in my opinion.</p>\n<p>For starters, like Randall Stephenson of<b>AT&amp;T</b>(NYSE:<b><u>T</u></b>), she prioritized the dividend and missed the cloud — a trillion-dollar opportunity. Additionally, like Jeff Immelt of<b><a href=\"https://laohu8.com/S/BGC\">General</a> Electric</b>(NYSE:<b><u>GE</u></b>), she covered up poor performance with happy talk and buybacks. Then finally, like Brian Krzanich of<b><a href=\"https://laohu8.com/S/INTC\">Intel</a></b>(NASDAQ:<b><u>INTC</u></b>), Rometty ran off talent until the cupboard was bare.</p>\n<p>When I was young, IBM dominated technology just like the Cowboys dominated football. They literally<i>made</i><b><a href=\"https://laohu8.com/S/MSFT\">Microsoft</a></b>(NASDAQ:<b><u>MSFT</u></b>) and used it to crush<b><a href=\"https://laohu8.com/S/AAPL\">Apple</a></b>(NASDAQ:<b><u>AAPL</u></b>) in PCs. Their style was to bring in suits who assured clients they could handle all of their computing. Their Jimmy Johnson (another football icon) was Lou Gerstner, who made IBM a consulting company. Gerstner even wrote a book about it called<i>Who Says Elephants Can’t Dance.</i></p>\n<p>Whitehurst also has a book,<i>The Open Organization</i>, which describes how successful companies today must be run from the bottom-up as much as the top-down. Tech companies must also be partners with their customers, Whitehurst notes, not their overlords. The book was a direct challenge to the way IBM does business.</p>\n<p>When the companybought Red Hat, I was ready to buy IBM stock, thinking it would mark a transformation. However, Rometty and others have shown that’s not happening.</p>\n<p><b>Why IBM Looks Good</b></p>\n<p>Of course, IBM stock still looks good right now because everything in tech looks good. Today, shares are up 12% year-to-date (YTD) and have paid out $3.27 per share in dividends. Thesecond-quarter earningslooked good as well. Now, investors are hoping that, byspinning offits services business as Kyndryl,&nbsp; IBM can be great again.</p>\n<p>But that’s not going to happen. Kyndryl has signed an expensive leaseatop One Vanderbilt. It’s a sales office, meant to over-awe clients with its power. That’s the IBM way. But Kyndryl is just an outsourcer like<b>Cognizant</b>(NASDAQ:<b><u>CTSH</u></b>), which has also gone nowhere this year.</p>\n<p>And the rest of IBM? It will be a minnow among giants.<b><a href=\"https://laohu8.com/S/DVMT\">Dell</a></b>&nbsp;(NYSE:<b><u>DELL</u></b>), which is similar to the company and owns most of<b>VMWare</b>(NYSE:<b><u>VMW</u></b>), is up 31% YTD. Likewise,<b><a href=\"https://laohu8.com/S/ORCL\">Oracle</a></b>(NYSE:<b><u>ORCL</u></b>) — the faux cloud company that Silicon Valley loves to hate — is up 39% YTD.</p>\n<p>Of course, the “hybrid cloud” is agreat idea,but IBM can’t execute on it. After all, Dak Prescott is also a good quarterback, but that doesn’t mean he can carry the team.</p>\n<p><b>The Bottom Line on IBM Stock</b></p>\n<p>If one word can be used to describe IBM today,it’s Watson.</p>\n<p>Watson was named for the company’s legendary CEOs, Tom Watson Sr. — who created IBM —&nbsp; and Tom Watson Jr., who made IBM a computer company. It was supposed to become a dominant artificial intelligence (AI) engine.</p>\n<p>In the end, though, Watson was justApache Hadoopwith a fancy front-end. Hadoop was an interesting idea, but a business failure.</p>\n<p>When it comes down to it, IBM needs to be recycled, like its old upstate <a href=\"https://laohu8.com/S/NWY\">New York</a> manufacturing plantsneed to be recycled. My guess is that it will be, after the company has flailed a bit as this latest incarnation. Its cloud will become a real estate investment trust (REIT) like<b><a href=\"https://laohu8.com/S/EQIX\">Equinix</a></b>(NASDAQ:<b><u>EQIX</u></b>) and Red Hat will be spun out on its own. Retirement liabilities will be made to disappear.</p>\n<p>But IBM won’t be taken out for nearly the $126 billion it’s worth today. That’s because, in my opinion, Virginia Rometty has become the Jerry Jones of technology. She’ll win eight games and lose eight games, then call it a success. Consider that before investing in IBM stock.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Still Living in the Past, IBM Remains Behind the Tech Ball</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStill Living in the Past, IBM Remains Behind the Tech Ball\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 20:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/07/ibm-stock-still-living-in-past-ibm-remains-behind-the-tech-ball/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>IBM hasn't had any wins in a quarter century -- and it's not about to start. Here's what's behind IBM stock.\n\nTo make a comparison to football, IBM is the Dallas Cowboys of technology. How do I mean? ...</p>\n\n<a href=\"https://investorplace.com/2021/07/ibm-stock-still-living-in-past-ibm-remains-behind-the-tech-ball/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IBM":"IBM"},"source_url":"https://investorplace.com/2021/07/ibm-stock-still-living-in-past-ibm-remains-behind-the-tech-ball/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1175975559","content_text":"IBM hasn't had any wins in a quarter century -- and it's not about to start. Here's what's behind IBM stock.\n\nTo make a comparison to football, IBM is the Dallas Cowboys of technology. How do I mean? Well, both IBM and the Cowboys are overrated. They haven’t won a title in a quarter century and they’re not going to do it this year. Their system is stale, yet somehow they still have fans. All around, IBM stock represents a disappointment.\nSource: shutterstock.com/LCV\nBasically, both the Cowboys and IBM are living in the past. The Cowboys revere football icon Tom Landry while actually being run by Jerry Jones. Similarly, IBM still reveres its 20th century leaders while still feeling the effects of former CEO and current executive chairmanVirginia Rometty.\nThis much became clear when Jim Whitehurst, who brought IBM a new cachet with Red Hat in 2019,announced his departure. Rometty and the IBM bureaucracy outmaneuvered him, installing Arvind Krishna as CEO. Now, the company is still behind the ball.\nIBM Stock: Rometty’s Bad Plays\nRometty — who became CEO in 2012 after a career in marketing — compiled one of the worst executive records of the last decade in my opinion.\nFor starters, like Randall Stephenson ofAT&T(NYSE:T), she prioritized the dividend and missed the cloud — a trillion-dollar opportunity. Additionally, like Jeff Immelt ofGeneral Electric(NYSE:GE), she covered up poor performance with happy talk and buybacks. Then finally, like Brian Krzanich ofIntel(NASDAQ:INTC), Rometty ran off talent until the cupboard was bare.\nWhen I was young, IBM dominated technology just like the Cowboys dominated football. They literallymadeMicrosoft(NASDAQ:MSFT) and used it to crushApple(NASDAQ:AAPL) in PCs. Their style was to bring in suits who assured clients they could handle all of their computing. Their Jimmy Johnson (another football icon) was Lou Gerstner, who made IBM a consulting company. Gerstner even wrote a book about it calledWho Says Elephants Can’t Dance.\nWhitehurst also has a book,The Open Organization, which describes how successful companies today must be run from the bottom-up as much as the top-down. Tech companies must also be partners with their customers, Whitehurst notes, not their overlords. The book was a direct challenge to the way IBM does business.\nWhen the companybought Red Hat, I was ready to buy IBM stock, thinking it would mark a transformation. However, Rometty and others have shown that’s not happening.\nWhy IBM Looks Good\nOf course, IBM stock still looks good right now because everything in tech looks good. Today, shares are up 12% year-to-date (YTD) and have paid out $3.27 per share in dividends. Thesecond-quarter earningslooked good as well. Now, investors are hoping that, byspinning offits services business as Kyndryl,  IBM can be great again.\nBut that’s not going to happen. Kyndryl has signed an expensive leaseatop One Vanderbilt. It’s a sales office, meant to over-awe clients with its power. That’s the IBM way. But Kyndryl is just an outsourcer likeCognizant(NASDAQ:CTSH), which has also gone nowhere this year.\nAnd the rest of IBM? It will be a minnow among giants.Dell (NYSE:DELL), which is similar to the company and owns most ofVMWare(NYSE:VMW), is up 31% YTD. Likewise,Oracle(NYSE:ORCL) — the faux cloud company that Silicon Valley loves to hate — is up 39% YTD.\nOf course, the “hybrid cloud” is agreat idea,but IBM can’t execute on it. After all, Dak Prescott is also a good quarterback, but that doesn’t mean he can carry the team.\nThe Bottom Line on IBM Stock\nIf one word can be used to describe IBM today,it’s Watson.\nWatson was named for the company’s legendary CEOs, Tom Watson Sr. — who created IBM —  and Tom Watson Jr., who made IBM a computer company. It was supposed to become a dominant artificial intelligence (AI) engine.\nIn the end, though, Watson was justApache Hadoopwith a fancy front-end. Hadoop was an interesting idea, but a business failure.\nWhen it comes down to it, IBM needs to be recycled, like its old upstate New York manufacturing plantsneed to be recycled. My guess is that it will be, after the company has flailed a bit as this latest incarnation. Its cloud will become a real estate investment trust (REIT) likeEquinix(NASDAQ:EQIX) and Red Hat will be spun out on its own. Retirement liabilities will be made to disappear.\nBut IBM won’t be taken out for nearly the $126 billion it’s worth today. That’s because, in my opinion, Virginia Rometty has become the Jerry Jones of technology. She’ll win eight games and lose eight games, then call it a success. Consider that before investing in IBM stock.","news_type":1},"isVote":1,"tweetType":1,"viewCount":78,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":881541834,"gmtCreate":1631369712128,"gmtModify":1632882920567,"author":{"id":"4087953198586960","authorId":"4087953198586960","name":"Smart74","avatar":"https://static.tigerbbs.com/03a3700aaa7249889bedd5bd5e73f9ae","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087953198586960","authorIdStr":"4087953198586960"},"themes":[],"htmlText":"Great and useful","listText":"Great and useful","text":"Great and useful","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/881541834","repostId":"2166376256","repostType":4,"isVote":1,"tweetType":1,"viewCount":101,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":855008424,"gmtCreate":1635309283667,"gmtModify":1635309283667,"author":{"id":"4087953198586960","authorId":"4087953198586960","name":"Smart74","avatar":"https://static.tigerbbs.com/03a3700aaa7249889bedd5bd5e73f9ae","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087953198586960","authorIdStr":"4087953198586960"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/855008424","repostId":"1102311120","repostType":4,"repost":{"id":"1102311120","pubTimestamp":1635306080,"share":"https://www.laohu8.com/m/news/1102311120?lang=&edition=full","pubTime":"2021-10-27 11:41","market":"us","language":"en","title":"Why It Might Be the Right Time to Buy Warby Parker Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1102311120","media":"Barrons","summary":"Warby Parker‘s stock is up about 6% since the eyewear provider went public last month. Some analysts","content":"<p></p>\n<p>Warby Parker‘s stock is up about 6% since the eyewear provider went public last month. Some analysts said the company has found its niche in the optical retail sector.</p>\n<p>Warby Parker’s (ticker: WRBY) growth is being fueled by the success of its bricks-and-mortar stores and an aging population in need of affordable optical retailers.</p>\n<p>“How I think about Warby Parker is that they’ve completely cut out all the middlemen,” said Loop Capital Markets analyst Anthony Chukumba. “Essentially, they’re designing their own glasses, their own brands and then they’re directly sourcing those brands.”</p>\n<p>Chukumba also said the company has been successful in navigating their bricks-and-mortar sales. Consumers find the stores vibrant, he said, a bit different from buying glasses directly in the optometrist’s office.</p>\n<p>Shopping for glasses online is a challenge, he said, so having both e-commerce options and in-store options has proved fruitful.</p>\n<p>Store visits were up 32.4% in July, 19.2% in August, and 25.4% in September, from the same months in 2019, according to data compiled by Pacer.ai.</p>\n<p>Warby Parker “is one of the first direct-to-consumer companies that proved the traditionally brick-and-mortar-driven eyewear industry can go digital, and the company continues to push the boundaries of traditional vision care through virtual vision testing, virtual eyeglass try-ons and telehealth,” Cowen analyst Oliver Chen wrote in a research note.</p>\n<p>He wrote that the stock is a Buy, but that’s somewhat contingent on whether or not Warby Parker expands its store footprint. Both analysts noted this as a possible risk.</p>\n<p>“The oligopolistic nature of the U.S. eyewear market carries highbarriers to entry and could pose extreme challenges to WRBY’s path to becoming a holistic vision company,” Chen wrote.</p>\n<p>Some of those risks also include whether or not Warby Parker can continue to execute store roll outs and if competitors offer lower prices.</p>\n<p>The stock fell 2.5% to $57.53 on Tuesday. The S&amp;P 500 index rose 0.2%</p>\n<p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why It Might Be the Right Time to Buy Warby Parker Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy It Might Be the Right Time to Buy Warby Parker Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-27 11:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/buy-warby-parker-stock-51635268656?mod=RTA><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Warby Parker‘s stock is up about 6% since the eyewear provider went public last month. Some analysts said the company has found its niche in the optical retail sector.\nWarby Parker’s (ticker: WRBY) ...</p>\n\n<a href=\"https://www.barrons.com/articles/buy-warby-parker-stock-51635268656?mod=RTA\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"WRBY":"Warby Parker Inc."},"source_url":"https://www.barrons.com/articles/buy-warby-parker-stock-51635268656?mod=RTA","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102311120","content_text":"Warby Parker‘s stock is up about 6% since the eyewear provider went public last month. Some analysts said the company has found its niche in the optical retail sector.\nWarby Parker’s (ticker: WRBY) growth is being fueled by the success of its bricks-and-mortar stores and an aging population in need of affordable optical retailers.\n“How I think about Warby Parker is that they’ve completely cut out all the middlemen,” said Loop Capital Markets analyst Anthony Chukumba. “Essentially, they’re designing their own glasses, their own brands and then they’re directly sourcing those brands.”\nChukumba also said the company has been successful in navigating their bricks-and-mortar sales. Consumers find the stores vibrant, he said, a bit different from buying glasses directly in the optometrist’s office.\nShopping for glasses online is a challenge, he said, so having both e-commerce options and in-store options has proved fruitful.\nStore visits were up 32.4% in July, 19.2% in August, and 25.4% in September, from the same months in 2019, according to data compiled by Pacer.ai.\nWarby Parker “is one of the first direct-to-consumer companies that proved the traditionally brick-and-mortar-driven eyewear industry can go digital, and the company continues to push the boundaries of traditional vision care through virtual vision testing, virtual eyeglass try-ons and telehealth,” Cowen analyst Oliver Chen wrote in a research note.\nHe wrote that the stock is a Buy, but that’s somewhat contingent on whether or not Warby Parker expands its store footprint. Both analysts noted this as a possible risk.\n“The oligopolistic nature of the U.S. eyewear market carries highbarriers to entry and could pose extreme challenges to WRBY’s path to becoming a holistic vision company,” Chen wrote.\nSome of those risks also include whether or not Warby Parker can continue to execute store roll outs and if competitors offer lower prices.\nThe stock fell 2.5% to $57.53 on Tuesday. The S&P 500 index rose 0.2%","news_type":1},"isVote":1,"tweetType":1,"viewCount":334,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":827958512,"gmtCreate":1634395465276,"gmtModify":1634395465398,"author":{"id":"4087953198586960","authorId":"4087953198586960","name":"Smart74","avatar":"https://static.tigerbbs.com/03a3700aaa7249889bedd5bd5e73f9ae","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087953198586960","authorIdStr":"4087953198586960"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/827958512","repostId":"1132582737","repostType":4,"repost":{"id":"1132582737","pubTimestamp":1634311475,"share":"https://www.laohu8.com/m/news/1132582737?lang=&edition=full","pubTime":"2021-10-15 23:24","market":"us","language":"en","title":"JPMorgan On Amazon Stock: 29% Upside Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=1132582737","media":"TheStreet","summary":"Amazon stock has fallen victim of its own success: shares of the e-commerce giant have lagged the S&","content":"<p>Amazon stock has fallen victim of its own success: shares of the e-commerce giant have lagged the S&amp;P 500 since its disappointing Q2 earnings day. But JPMorgan is optimistic and sees upside ahead.</p>\n<p>Since the release of Amazon’s most recent earnings report, investors have watched shares of the cloud and e-commerce giant tank by 11%. Amazon stock&nbsp;underperformed an already weak S&amp;P 500 by three percentage points over the period, leaving some to question: is AMZN still a good investment?</p>\n<p>According to experts at JPMorgan (JPM), the answer is yes. Today, the Amazon Maven presents the main reasons why five-star&nbsp;rated&nbsp;analyst Doug Anmuth believes that Amazon stock is about to surge, producing an estimated 29% in gains through 2022.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8c8e5f4ca5aa3dba7bef61858521bd17\" tg-width=\"1240\" tg-height=\"827\" width=\"100%\" height=\"auto\"><span>Figure 1: J.P. Morgan offices in Hong Kong.</span></p>\n<p><b>Getting back on track</b></p>\n<p>As the&nbsp;Amazon Maven mentioned&nbsp;recently, the impact of the pandemic on shopping habits led analysts to overestimate Amazon’s revenues for the current year. This is the very first reason why JPMorgan&nbsp;believes&nbsp;that AMZN will get a green light to climb again: “[the stock is heading] closer to the last quarter of difficult COVID-19 comps in the first quarter of 2022\", which should help to reset sentiment.</p>\n<p>Once 2020 results are left in the rearview mirror, the e-commerce company will face more realistic, non-pandemic-inflated projections. As mentioned by Mr. Anmuth himself, \"further downward revisions to 2022 profit estimates would help lower the bar and potentially create more of a clearing event”.</p>\n<p><b>Holiday upside</b></p>\n<p>Another reason why Mr. Anmuth believes Amazon stock will head higher is the beginning of the holiday season. Since the market has been so cautious towards AMZN lately, the stock has been trading at lower multiples than would otherwise be considered reasonable. The holidays, on the other hand, could be the bullish catalyst that investors need to own the stock again.</p>\n<p>Lastly, there is the potential for an increase in Prime subscription price in 2022. Considering an estimated 150 million US Prime members in 2021, a $20 dollar hike in annual fee would lead to an extra $3 billion heading towards Amazon’s coffers.</p>\n<p>At first glance, the figure may not seem like much, given Amazon’s revenues of $380 billion in 2020. However, keep in mind that nearly all the price increase would flow cleanly into Amazon’s operating income. On a 2020 basis, this would represent growth of nearly 15% in pre-tax profits.</p>\n<p><b>What do other experts say?</b></p>\n<p>Other reports published recently also support the bullish thesis. Mark Mahaney from Evercore ISI&nbsp;talked&nbsp;to 15 industry experts, including former Amazon employees, during the research firm’s Amazon Day Symposium. The analyst liked what he saw and issued a hefty $4,700 target price.</p>\n<p>Wolfe Research’s Deepak Mathivanan, on the other hand,lowered&nbsp;his price target on AMZN modestly to $3,850 from $3,900, despite maintaining an outperform rating. Sitting closer to the consensus price target is Goldman Sachs’ Eric Sheridan, who is bullish and&nbsp;believes&nbsp;that AMZN shares are worth $4,250.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JPMorgan On Amazon Stock: 29% Upside Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJPMorgan On Amazon Stock: 29% Upside Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-15 23:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/amazon/news/jpmorgan-on-amazon-stock-29-upside-potential><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Amazon stock has fallen victim of its own success: shares of the e-commerce giant have lagged the S&P 500 since its disappointing Q2 earnings day. But JPMorgan is optimistic and sees upside ahead.\n...</p>\n\n<a href=\"https://www.thestreet.com/amazon/news/jpmorgan-on-amazon-stock-29-upside-potential\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊"},"source_url":"https://www.thestreet.com/amazon/news/jpmorgan-on-amazon-stock-29-upside-potential","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1132582737","content_text":"Amazon stock has fallen victim of its own success: shares of the e-commerce giant have lagged the S&P 500 since its disappointing Q2 earnings day. But JPMorgan is optimistic and sees upside ahead.\nSince the release of Amazon’s most recent earnings report, investors have watched shares of the cloud and e-commerce giant tank by 11%. Amazon stock underperformed an already weak S&P 500 by three percentage points over the period, leaving some to question: is AMZN still a good investment?\nAccording to experts at JPMorgan (JPM), the answer is yes. Today, the Amazon Maven presents the main reasons why five-star rated analyst Doug Anmuth believes that Amazon stock is about to surge, producing an estimated 29% in gains through 2022.\nFigure 1: J.P. Morgan offices in Hong Kong.\nGetting back on track\nAs the Amazon Maven mentioned recently, the impact of the pandemic on shopping habits led analysts to overestimate Amazon’s revenues for the current year. This is the very first reason why JPMorgan believes that AMZN will get a green light to climb again: “[the stock is heading] closer to the last quarter of difficult COVID-19 comps in the first quarter of 2022\", which should help to reset sentiment.\nOnce 2020 results are left in the rearview mirror, the e-commerce company will face more realistic, non-pandemic-inflated projections. As mentioned by Mr. Anmuth himself, \"further downward revisions to 2022 profit estimates would help lower the bar and potentially create more of a clearing event”.\nHoliday upside\nAnother reason why Mr. Anmuth believes Amazon stock will head higher is the beginning of the holiday season. Since the market has been so cautious towards AMZN lately, the stock has been trading at lower multiples than would otherwise be considered reasonable. The holidays, on the other hand, could be the bullish catalyst that investors need to own the stock again.\nLastly, there is the potential for an increase in Prime subscription price in 2022. Considering an estimated 150 million US Prime members in 2021, a $20 dollar hike in annual fee would lead to an extra $3 billion heading towards Amazon’s coffers.\nAt first glance, the figure may not seem like much, given Amazon’s revenues of $380 billion in 2020. However, keep in mind that nearly all the price increase would flow cleanly into Amazon’s operating income. On a 2020 basis, this would represent growth of nearly 15% in pre-tax profits.\nWhat do other experts say?\nOther reports published recently also support the bullish thesis. Mark Mahaney from Evercore ISI talked to 15 industry experts, including former Amazon employees, during the research firm’s Amazon Day Symposium. The analyst liked what he saw and issued a hefty $4,700 target price.\nWolfe Research’s Deepak Mathivanan, on the other hand,lowered his price target on AMZN modestly to $3,850 from $3,900, despite maintaining an outperform rating. Sitting closer to the consensus price target is Goldman Sachs’ Eric Sheridan, who is bullish and believes that AMZN shares are worth $4,250.","news_type":1},"isVote":1,"tweetType":1,"viewCount":528,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":807778566,"gmtCreate":1628063364355,"gmtModify":1633753932437,"author":{"id":"4087953198586960","authorId":"4087953198586960","name":"Smart74","avatar":"https://static.tigerbbs.com/03a3700aaa7249889bedd5bd5e73f9ae","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087953198586960","authorIdStr":"4087953198586960"},"themes":[],"htmlText":"Great!","listText":"Great!","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/807778566","repostId":"2156174967","repostType":4,"isVote":1,"tweetType":1,"viewCount":179,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":174233558,"gmtCreate":1627099846574,"gmtModify":1633767953220,"author":{"id":"4087953198586960","authorId":"4087953198586960","name":"Smart74","avatar":"https://static.tigerbbs.com/03a3700aaa7249889bedd5bd5e73f9ae","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087953198586960","authorIdStr":"4087953198586960"},"themes":[],"htmlText":"Great!","listText":"Great!","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/174233558","repostId":"2153751984","repostType":4,"repost":{"id":"2153751984","pubTimestamp":1627050780,"share":"https://www.laohu8.com/m/news/2153751984?lang=&edition=full","pubTime":"2021-07-23 22:33","market":"us","language":"en","title":"Got $1,000? Buy These Cheap Growth Stocks Right Away","url":"https://stock-news.laohu8.com/highlight/detail?id=2153751984","media":"Motley Fool","summary":"These growth stocks have made investors rich in the past, and they can keep doing so in the future.","content":"<p>It is difficult to find high-growth companies trading at attractive valuations, especially in the technology sector, where stocks usually trade at rich valuations. The rich valuations happen because they tend to outperform the broader market on the back of disruptive products and services that may fuel rapid long-term growth.</p>\n<p>Not surprisingly, the average price-to-earnings (P/E) ratio of the tech-heavy&nbsp;<b><a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a> 100</b> Index stands&nbsp;at 38.4 as compared to the <b>Dow Jones Industrial Average</b>'s average P/E ratio of 26.3 and the <b>S&amp;P 500</b>'s average multiple of 36.6.</p>\n<p>However, there are a few tech companies that continue to trade at attractive valuations despite crushing the broader market. <b><a href=\"https://laohu8.com/S/QRVO\">Qorvo</a></b> (NASDAQ:QRVO) and <b>Jabil</b> (NYSE:JBL) are two stocks that have made investors significantly richer over the past five years.</p>\n<p><img src=\"https://static.tigerbbs.com/549aaadbeda352ae2081da23ac1deb45\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"></p>\n<p>QRVO data by YCharts</p>\n<p>For example, a $1,000 investment in Qorvo five years ago would be worth almost $3,100 now. A similar investment in Jabil would be worth close to $2,700 now. The good part is that both companies could at least equal, if not outperform, their stellar gains in the coming years. Let's take a look at the reasons why it still makes sense to invest $1,000 in these tech stocks.</p>\n<h3>Qorvo: Riding the 5G wave</h3>\n<p>Qorvo is benefiting from multiple hot tech trends right now, but its biggest catalyst remains the 5G smartphone market. The chipmaker's revenue in fiscal 2021 (which ended on April 3) shot up 24% year over year to $4.02 billion. It finished the year with a gross profit margin of 46.9%, up substantially over the prior year's figure of 40.8%.</p>\n<p>Qorvo credited the \"higher demand for our 5G mobile solutions, 5G base station products, and Wi-Fi products\" for this impressive showing. The good news is that all these verticals are still in their early phases of growth. For instance, 5G smartphone shipments are expected to jump from an estimated 239 million units in 2020 to 1.12 billion units by 2025, according&nbsp;to Taiwan-based Market Intelligence &amp; Consulting Institute.</p>\n<p><img src=\"https://static.tigerbbs.com/4f9ffe2f3eb673512439f8114e7d18f2\" tg-width=\"700\" tg-height=\"510\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<p>With Qorvo getting just over 71% of its total&nbsp;revenue from the mobile products segment last quarter, the 5G smartphone boom is going to move the needle significantly for the company. After all, the chipmaker supplies its wireless components to the leading players in the 5G smartphone space, including <b><a href=\"https://laohu8.com/S/AAPL\">Apple</a></b> (NASDAQ:AAPL). The iPhone maker produced 30%&nbsp;of Qorvo's total revenue last fiscal year.</p>\n<p>This sizable reliance on Apple is a good thing for Qorvo as the tech giant is on fire in the 5G smartphone era. The iPhone 12 has been a runaway hit among consumers looking to make the move to a 5G device from their older iPhones, and there are at least 800 million customers in Apple's installed base that have yet to make the move to 5G. As a result, Apple is going to be a long-term catalyst for Qorvo's mobile business thanks to the massive iPhone volume opportunity at hand.</p>\n<p>Its relationship with other smartphone OEMs (original equipment manufacturers) such&nbsp;as <b>Samsung</b> and <b>Xiaomi</b> will also come in handy in the long run, as these companies are dominant&nbsp;players in the 5G smartphone market along with Apple.</p>\n<p>More importantly, the improved 5G smartphone volumes will help Qorvo generate faster revenue and earnings growth. That's because the radio-frequency (RF) content in mid-range 5G smartphones is doubling over their 4G predecessors, while high-end devices are witnessing an additional $5 to $7 in wireless content.</p>\n<p>Thanks to the 5G tailwind, Qorvo is anticipated to record 16% annual earnings growth for the next five years, up from the 6% annual growth seen in the last five years. This makes it an attractive growth stock to buy right now at 29.7 times trailing earnings, which is lower than the Nasdaq 100 Index's rich multiple we saw earlier.</p>\n<h3>Jabil: Diverse growth drivers should lead to better times</h3>\n<p>Jabil has made a fine comeback this year after the novel coronavirus pandemic derailed the company's growth in 2020. The contract electronics manufacturer delivered a solid third-quarter earnings report&nbsp;in June, recording 14% year-over-year revenue growth to $7.2 billion. Non-GAAP earnings had shot up to $1.30 per share during the quarter from $0.37 per share a year ago. <b>&nbsp;</b></p>\n<p>Even better, Jabil upgraded its full-year guidance on the back of impressive momentum in the cloud, mobility, semiconductor, automotive, and connected devices markets. These end markets are on track to grow nicely for Jabil this year and beyond.</p>\n<p>In mobility, for instance, Jabil expects $4.1 billion in revenue this fiscal year, up 24% over fiscal 2020. That's not surprising as 20%&nbsp;of the company's total revenue comes from manufacturing casings for Apple's iPhone and iPad. We have already seen that Apple's 5G iPhones are selling like hotcakes, and they can keep doing so thanks to an upgrade supercycle that's currently playing out. This should rub off positively on Jabil's prospects as well since it has a close relationship with Apple.</p>\n<p>However, Jabil draws its revenue from a wider number of verticals. The automotive and transportation segment, for example, is expected&nbsp;to deliver $2.2 billion in revenue this year, up 29% from last year. This business seems to have solid long-term potential as the global automotive contract manufacturing space is expected to clock 7.2% annual growth through 2027, according&nbsp;to a third-party estimate.</p>\n<p>Similarly, Jabil provides contract manufacturing services to connected device manufacturers, semiconductor capital equipment makers, cloud computing customers, and networking and storage providers, among others. Grand View Research estimates&nbsp;that the global contract electronics manufacturing market could be worth $800 billion by 2027 as compared to $417 billion at the end of 2019.</p>\n<p>Not surprisingly, Jabil's bottom line is expected to grow at nearly 20% per year for the next five years, as it seems to be on track to take advantage of the huge end-market opportunity that lies ahead. And now would be a great time to buy this tech stock as it is trading at just 14 times trailing earnings, which makes it way cheaper&nbsp;than the indexes discussed earlier. What's more, Jabil's forward earnings multiple of just 9.3 makes it even more attractive, giving investors another great reason to consider putting $1,000 in the stock.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $1,000? Buy These Cheap Growth Stocks Right Away</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $1,000? Buy These Cheap Growth Stocks Right Away\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-23 22:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/23/got-1000-buy-these-cheap-growth-stocks-right-away/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It is difficult to find high-growth companies trading at attractive valuations, especially in the technology sector, where stocks usually trade at rich valuations. The rich valuations happen because ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/23/got-1000-buy-these-cheap-growth-stocks-right-away/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"03086":"华夏纳指","AAPL":"苹果","QRVO":"Qorvo, Inc.","09086":"华夏纳指-U"},"source_url":"https://www.fool.com/investing/2021/07/23/got-1000-buy-these-cheap-growth-stocks-right-away/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153751984","content_text":"It is difficult to find high-growth companies trading at attractive valuations, especially in the technology sector, where stocks usually trade at rich valuations. The rich valuations happen because they tend to outperform the broader market on the back of disruptive products and services that may fuel rapid long-term growth.\nNot surprisingly, the average price-to-earnings (P/E) ratio of the tech-heavy Nasdaq 100 Index stands at 38.4 as compared to the Dow Jones Industrial Average's average P/E ratio of 26.3 and the S&P 500's average multiple of 36.6.\nHowever, there are a few tech companies that continue to trade at attractive valuations despite crushing the broader market. Qorvo (NASDAQ:QRVO) and Jabil (NYSE:JBL) are two stocks that have made investors significantly richer over the past five years.\n\nQRVO data by YCharts\nFor example, a $1,000 investment in Qorvo five years ago would be worth almost $3,100 now. A similar investment in Jabil would be worth close to $2,700 now. The good part is that both companies could at least equal, if not outperform, their stellar gains in the coming years. Let's take a look at the reasons why it still makes sense to invest $1,000 in these tech stocks.\nQorvo: Riding the 5G wave\nQorvo is benefiting from multiple hot tech trends right now, but its biggest catalyst remains the 5G smartphone market. The chipmaker's revenue in fiscal 2021 (which ended on April 3) shot up 24% year over year to $4.02 billion. It finished the year with a gross profit margin of 46.9%, up substantially over the prior year's figure of 40.8%.\nQorvo credited the \"higher demand for our 5G mobile solutions, 5G base station products, and Wi-Fi products\" for this impressive showing. The good news is that all these verticals are still in their early phases of growth. For instance, 5G smartphone shipments are expected to jump from an estimated 239 million units in 2020 to 1.12 billion units by 2025, according to Taiwan-based Market Intelligence & Consulting Institute.\n\nImage source: Getty Images.\nWith Qorvo getting just over 71% of its total revenue from the mobile products segment last quarter, the 5G smartphone boom is going to move the needle significantly for the company. After all, the chipmaker supplies its wireless components to the leading players in the 5G smartphone space, including Apple (NASDAQ:AAPL). The iPhone maker produced 30% of Qorvo's total revenue last fiscal year.\nThis sizable reliance on Apple is a good thing for Qorvo as the tech giant is on fire in the 5G smartphone era. The iPhone 12 has been a runaway hit among consumers looking to make the move to a 5G device from their older iPhones, and there are at least 800 million customers in Apple's installed base that have yet to make the move to 5G. As a result, Apple is going to be a long-term catalyst for Qorvo's mobile business thanks to the massive iPhone volume opportunity at hand.\nIts relationship with other smartphone OEMs (original equipment manufacturers) such as Samsung and Xiaomi will also come in handy in the long run, as these companies are dominant players in the 5G smartphone market along with Apple.\nMore importantly, the improved 5G smartphone volumes will help Qorvo generate faster revenue and earnings growth. That's because the radio-frequency (RF) content in mid-range 5G smartphones is doubling over their 4G predecessors, while high-end devices are witnessing an additional $5 to $7 in wireless content.\nThanks to the 5G tailwind, Qorvo is anticipated to record 16% annual earnings growth for the next five years, up from the 6% annual growth seen in the last five years. This makes it an attractive growth stock to buy right now at 29.7 times trailing earnings, which is lower than the Nasdaq 100 Index's rich multiple we saw earlier.\nJabil: Diverse growth drivers should lead to better times\nJabil has made a fine comeback this year after the novel coronavirus pandemic derailed the company's growth in 2020. The contract electronics manufacturer delivered a solid third-quarter earnings report in June, recording 14% year-over-year revenue growth to $7.2 billion. Non-GAAP earnings had shot up to $1.30 per share during the quarter from $0.37 per share a year ago.  \nEven better, Jabil upgraded its full-year guidance on the back of impressive momentum in the cloud, mobility, semiconductor, automotive, and connected devices markets. These end markets are on track to grow nicely for Jabil this year and beyond.\nIn mobility, for instance, Jabil expects $4.1 billion in revenue this fiscal year, up 24% over fiscal 2020. That's not surprising as 20% of the company's total revenue comes from manufacturing casings for Apple's iPhone and iPad. We have already seen that Apple's 5G iPhones are selling like hotcakes, and they can keep doing so thanks to an upgrade supercycle that's currently playing out. This should rub off positively on Jabil's prospects as well since it has a close relationship with Apple.\nHowever, Jabil draws its revenue from a wider number of verticals. The automotive and transportation segment, for example, is expected to deliver $2.2 billion in revenue this year, up 29% from last year. This business seems to have solid long-term potential as the global automotive contract manufacturing space is expected to clock 7.2% annual growth through 2027, according to a third-party estimate.\nSimilarly, Jabil provides contract manufacturing services to connected device manufacturers, semiconductor capital equipment makers, cloud computing customers, and networking and storage providers, among others. Grand View Research estimates that the global contract electronics manufacturing market could be worth $800 billion by 2027 as compared to $417 billion at the end of 2019.\nNot surprisingly, Jabil's bottom line is expected to grow at nearly 20% per year for the next five years, as it seems to be on track to take advantage of the huge end-market opportunity that lies ahead. And now would be a great time to buy this tech stock as it is trading at just 14 times trailing earnings, which makes it way cheaper than the indexes discussed earlier. What's more, Jabil's forward earnings multiple of just 9.3 makes it even more attractive, giving investors another great reason to consider putting $1,000 in the stock.","news_type":1},"isVote":1,"tweetType":1,"viewCount":87,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172227920,"gmtCreate":1626963420260,"gmtModify":1633769319400,"author":{"id":"4087953198586960","authorId":"4087953198586960","name":"Smart74","avatar":"https://static.tigerbbs.com/03a3700aaa7249889bedd5bd5e73f9ae","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087953198586960","authorIdStr":"4087953198586960"},"themes":[],"htmlText":"Useful information&nbsp;","listText":"Useful information&nbsp;","text":"Useful information","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/172227920","repostId":"2153711620","repostType":4,"repost":{"id":"2153711620","pubTimestamp":1626958500,"share":"https://www.laohu8.com/m/news/2153711620?lang=&edition=full","pubTime":"2021-07-22 20:55","market":"us","language":"en","title":"This Seemingly Flawless Social Security Strategy Could Backfire on You","url":"https://stock-news.laohu8.com/highlight/detail?id=2153711620","media":"Motley Fool","summary":"One popular way to score more money may not actually work the way you expect it to.","content":"<p>Many seniors rely on Social Security to provide a fair chunk of their retirement income. And there's a good chance you'll eventually do the same. As such, it's important to get as much money out of the program as you can.</p>\n<p>Now you'll often hear that a guaranteed way to snag a higher monthly benefit is to file for Social Security after full retirement age, or FRA. FRA is when you can collect the monthly benefit you're entitled to based on your earnings history. If you were born in 1960 or later, FRA kicks in at 67.</p>\n<p>Of course, many seniors rush to claim their benefits ahead of FRA -- you can do so starting at age 62 -- and shrink those monthly payments in the process. But for each month you delay your filing beyond FRA, your benefit will increase by about 2/3 of 1%. Or, to put it another way, for each year you delay your filing, your benefits will grow by 8%.</p>\n<p><img src=\"https://static.tigerbbs.com/ebe0f69b45d8694322ca43a2fd3d46fc\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<p>The delayed retirement credits you'll accrue by postponing your filing will stop accumulating once you turn 70. As such, 70 is generally considered the latest age to sign up for Social Security, even though you could technically opt to delay your filing beyond that point. And if you're looking at a FRA of 67, filing at 70 means boosting your benefits by a rather impressive 24%.</p>\n<p>But while you'll often hear that delaying your filing until age 70 is a surefire way to grow your benefits, that strategy could also come back to bite you. Here's why.</p>\n<h3>Look at the big picture</h3>\n<p>Delaying your filing beyond FRA will give you a higher benefit on a monthly basis. But will it give you a higher<i> lifetime</i> benefit? Maybe not.</p>\n<p>Filing for Social Security at age 70 makes sense when you expect to live a reasonably long life. But if you don't think that'll happen, whether due to preexisting health issues or your family history, then delaying your filing as long as possible may not be the best way to get more money out of Social Security.</p>\n<p>Say you're entitled to a $1,500 monthly benefit at a FRA of 67. Waiting until age 70 to file will give you $1,860 a month instead.</p>\n<p>If you live until age 82 1/2, you'll break even -- meaning, you'll end up collecting $279,000 whether you file at FRA or wait until age 70. But if you only live until the age of 78, delaying your filing until age 70 will actually cause you to lose out on over $19,400 in lifetime benefits, even though your monthly benefit will be higher.</p>\n<p>It's for this reason that the strategy of delaying Social Security may not be the best <a href=\"https://laohu8.com/S/AONE.U\">one</a> for you. Though it's impossible to predict your own mortality, you will need to face the reality that holding off on filing carries some risk. So if your goal is to get as much money out of Social Security as you possibly can, an earlier filing date may be a better choice.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Seemingly Flawless Social Security Strategy Could Backfire on You</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Seemingly Flawless Social Security Strategy Could Backfire on You\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 20:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/retirement/2021/07/22/this-seemingly-flawless-social-security-strategy-c/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Many seniors rely on Social Security to provide a fair chunk of their retirement income. And there's a good chance you'll eventually do the same. As such, it's important to get as much money out of ...</p>\n\n<a href=\"https://www.fool.com/retirement/2021/07/22/this-seemingly-flawless-social-security-strategy-c/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/retirement/2021/07/22/this-seemingly-flawless-social-security-strategy-c/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153711620","content_text":"Many seniors rely on Social Security to provide a fair chunk of their retirement income. And there's a good chance you'll eventually do the same. As such, it's important to get as much money out of the program as you can.\nNow you'll often hear that a guaranteed way to snag a higher monthly benefit is to file for Social Security after full retirement age, or FRA. FRA is when you can collect the monthly benefit you're entitled to based on your earnings history. If you were born in 1960 or later, FRA kicks in at 67.\nOf course, many seniors rush to claim their benefits ahead of FRA -- you can do so starting at age 62 -- and shrink those monthly payments in the process. But for each month you delay your filing beyond FRA, your benefit will increase by about 2/3 of 1%. Or, to put it another way, for each year you delay your filing, your benefits will grow by 8%.\n\nImage source: Getty Images.\nThe delayed retirement credits you'll accrue by postponing your filing will stop accumulating once you turn 70. As such, 70 is generally considered the latest age to sign up for Social Security, even though you could technically opt to delay your filing beyond that point. And if you're looking at a FRA of 67, filing at 70 means boosting your benefits by a rather impressive 24%.\nBut while you'll often hear that delaying your filing until age 70 is a surefire way to grow your benefits, that strategy could also come back to bite you. Here's why.\nLook at the big picture\nDelaying your filing beyond FRA will give you a higher benefit on a monthly basis. But will it give you a higher lifetime benefit? Maybe not.\nFiling for Social Security at age 70 makes sense when you expect to live a reasonably long life. But if you don't think that'll happen, whether due to preexisting health issues or your family history, then delaying your filing as long as possible may not be the best way to get more money out of Social Security.\nSay you're entitled to a $1,500 monthly benefit at a FRA of 67. Waiting until age 70 to file will give you $1,860 a month instead.\nIf you live until age 82 1/2, you'll break even -- meaning, you'll end up collecting $279,000 whether you file at FRA or wait until age 70. But if you only live until the age of 78, delaying your filing until age 70 will actually cause you to lose out on over $19,400 in lifetime benefits, even though your monthly benefit will be higher.\nIt's for this reason that the strategy of delaying Social Security may not be the best one for you. Though it's impossible to predict your own mortality, you will need to face the reality that holding off on filing carries some risk. So if your goal is to get as much money out of Social Security as you possibly can, an earlier filing date may be a better choice.","news_type":1},"isVote":1,"tweetType":1,"viewCount":129,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":813506813,"gmtCreate":1630210115732,"gmtModify":1704957088579,"author":{"id":"4087953198586960","authorId":"4087953198586960","name":"Smart74","avatar":"https://static.tigerbbs.com/03a3700aaa7249889bedd5bd5e73f9ae","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087953198586960","authorIdStr":"4087953198586960"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/813506813","repostId":"2162602132","repostType":4,"repost":{"id":"2162602132","pubTimestamp":1630076857,"share":"https://www.laohu8.com/m/news/2162602132?lang=&edition=full","pubTime":"2021-08-27 23:07","market":"us","language":"en","title":"Which Biotech Stock Will Shock the Market in 2022?","url":"https://stock-news.laohu8.com/highlight/detail?id=2162602132","media":"Motley Fool","summary":"Over the last few years, three tiny biotechs emerged out of nowhere to give amazing returns to early investors. Which biotech might pull off a similar feat in 2022?","content":"<p>In 2019, tiny&nbsp;<b><a href=\"https://laohu8.com/S/AXSM\">Axsome Therapeutics</a>&nbsp;</b>(NASDAQ:AXSM) emerged from micro-cap obscurity to become the best-performing stock in the market, rising by an amazing 3,600% in a year. In 2020, another tiny biotech,&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;</b>(NASDAQ:NVAX), came out of nowhere to stomp the stock market, with its share price skyrocketing by 2,700%. For most of 2021, yet another small biotech has been the top-performing stock in the market, as&nbsp;<b><a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a> </b>(NASDAQ:SAVA) jumped from under $7 a share in January to $123 a share on Aug. 24. (Whether it will keep its lead is another question, as the volatility is savage -- the stock is down to $52 as of Friday morning after news of a citizen petition against the company.)</p>\n<p>What's fascinating about the biotech sector in particular is how fast it moves. The sector is notorious for amazing price swings -- in either direction -- that can happen overnight. So why is that? Why are biotech stocks in particular so volatile? Why do they keep leading the market every year? And what biotech stock might -- repeat, <i>might&nbsp;</i>-- pull off this feat next year? Let's analyze why Axsome, Novavax, and Cassava zoomed higher over the last few years, and why I think <b><a href=\"https://laohu8.com/S/PIRS\">Pieris Pharmaceuticals</a> </b>(NASDAQ:PIRS) has a chance at a similar remarkable performance in 2022.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F638648%2Fgettyimages-108224060.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"465\" referrerpolicy=\"no-referrer\"></p>\n<h2>Biotech winners tend to start off tiny</h2>\n<p>The main reason these stocks were able to soar so impressively is that all three started with very tiny market caps. At the end of 2018, Axsome Therapeutics had a micro-cap valuation of $85 million. In 2019, Novavax stock fell to below $1, and the company had to do a 1-for-20 reverse split in order to keep its shares listed on the <b><a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a></b>. And at the beginning of 2020, Cassava had barely achieved small-cap status, with its market cap hovering at $240 million.</p>\n<p>So all three barn-burning stocks started off unloved by the market. Why does a biotech stock get so cheap? Probably the most common reason is the market believes the company's science is bad. Novavax, for instance, had a notable failure in its quest for a respiratory syncytial virus (RSV) vaccine. This clinical trial failure sent investors to the exits and sent the stock down into a crater in 2019, when it plunged to $4 a share (or $0.20 pre-split).</p>\n<p>Yet the market was spectacularly wrong about Novavax. While the company's RSV drug was a failure, Novavax had another drug in clinical trials, a flu vaccine. And this drug was a world-beater. It was flying through clinical trials, and it had defeated the market-leading flu vaccines from <b><a href=\"https://laohu8.com/S/SNY\">Sanofi SA</a></b>&nbsp;(NASDAQ:SNY) over and over again.</p>\n<p>In 2019, Novavax had the label of \"bad science,\" but the data for a different drug said otherwise. Sometimes companies with tiny market caps actually have compelling drugs that are performing exceptionally well in clinical trials. If you find such a company, you might want to buy some shares.</p>\n<h2>Is there enough money for a phase 3 trial?</h2>\n<p>That said, it's not enough just to have good science. Nobody is allowed to market their drugs to the public until that science has been validated in clinical trials and approved by the U.S. Food and Drug Administration -- and clinical trials cost a huge amount of money. Thus, before investing, it's important to determine whether the biotech has enough cash for a phase 3 trial. If the answer is \"no,\" the drug is stalled and won't go anywhere.</p>\n<p>Many unprofitable biotech companies finesse the money issue by collaborating with Big Pharma. When you see such a collaboration, you can have faith that there's enough cash for a phase 3 trial. However, these arrangements also often mean that the bigger pharmaceutical company acquires the rights to the molecule. And that can be like like selling off your future in order to pay the bills today.</p>\n<p>Interestingly, neither Axsome nor Novavax nor Cassava have an active collaboration with any big-pharma leaders. Instead, all three of these companies have elected to own 100% of the rights to their lead molecules. While the median expense for a phase 3 trial is $19 million, the numbers can vary dramatically, depending on how large the patient population is. I'd be nervous if a biotech had less than $100 million in cash (each of these has more). There's no question this independent approach is riskier, but also potentially a lot more rewarding.</p>\n<p>Biotech investors often like to see collaboration with Big Pharma -- it's a validation of the science, and it removes a lot of financial worries for small companies. But if you're chasing big rewards, you might want to look at biotech companies that are still independent (and have enough cash to stay that way).</p>\n<h2>Can Pieris pull off a miracle run in 2022?</h2>\n<p>Pieris stock is very cheap right now, with a $291 million valuation. (You know a stock is cheap when it could have a 10-bagger and still qualify as a small-cap!) Is the stock so cheap because its science is bad?</p>\n<p>It would probably be more accurate to say that Pieris' science is unproven. Like many unprofitable biotechs, Pieris doesn't have a drug in phase 3 trials yet. In fact, we're still waiting on positive phase 2 data. So it's early, and that's a danger sign. The reason Axsome, Novavax, and Cassava all skyrocketed is that all three companies made the journey from unproven drug to pivotal trials very quickly. Pieris is a few years away.</p>\n<p>Another major difference is that Pieris has signed multiple collaborative deals -- with <b>Roche</b>, <b>AstraZeneca</b>, and <b>Seagen</b>, among others. In <a href=\"https://laohu8.com/S/AONE.U\">one</a> sense that's good news, because it means that money for clinical trials isn't an issue for the company. Any drugs that work will make it to phase 3 trials and beyond. And all this collaboration adds confidence that the company is on the right track.</p>\n<p>Is Pieris sacrificing its future to pay for its present? In my opinion, no. While AstraZeneca now has rights to the company's asthma drug (its lead molecule), what makes Pieris such an exciting stock is not <a href=\"https://laohu8.com/S/AONE.U\">one</a> particular drug, but the company's entire platform. Pieris owns the rights to all the Anticalin proteins, and its library contains more than 100 billion of these new molecules. Anticalins are much smaller than antibodies, and as such can go where antibodies cannot. AstraZeneca paid big bucks for the rights to Pieris' asthma drug because that Anticalin molecule is small enough to go directly to the lung.</p>\n<p>I love the risk/reward equation for Pieris. If the company's drugs actually work -- we'll have data in that regard next year -- the stock will shoot much higher. Under its existing collaboration agreements, Pieris might make up to $9 billion if its Anticalin drugs reach certain milestones.&nbsp;But what will really make the stock take off is if/when other pharmaceutical players start making deals to add some of the company's Anticalin molecules to their pipelines.</p>\n<p>How do you value an entire new class of pharmaceuticals? Well, in 2019, worldwide sales for monoclonal antibodies (mAbs) totaled <i>$163 billion</i>. If Pieris' partners report any positive data on its Anticalin drugs next year, the upside for this stock is enormous.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Which Biotech Stock Will Shock the Market in 2022?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhich Biotech Stock Will Shock the Market in 2022?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-27 23:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/27/which-biotech-stock-will-shock-the-market-in-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In 2019, tiny Axsome Therapeutics (NASDAQ:AXSM) emerged from micro-cap obscurity to become the best-performing stock in the market, rising by an amazing 3,600% in a year. In 2020, another tiny biotech...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/27/which-biotech-stock-will-shock-the-market-in-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PIRS":"Pieris Pharmaceuticals, Inc.","SAVA":"Cassava Sciences Inc","AXSM":"Axsome Therapeutics, Inc.","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/27/which-biotech-stock-will-shock-the-market-in-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2162602132","content_text":"In 2019, tiny Axsome Therapeutics (NASDAQ:AXSM) emerged from micro-cap obscurity to become the best-performing stock in the market, rising by an amazing 3,600% in a year. In 2020, another tiny biotech, Novavax (NASDAQ:NVAX), came out of nowhere to stomp the stock market, with its share price skyrocketing by 2,700%. For most of 2021, yet another small biotech has been the top-performing stock in the market, as Cassava Sciences Inc (NASDAQ:SAVA) jumped from under $7 a share in January to $123 a share on Aug. 24. (Whether it will keep its lead is another question, as the volatility is savage -- the stock is down to $52 as of Friday morning after news of a citizen petition against the company.)\nWhat's fascinating about the biotech sector in particular is how fast it moves. The sector is notorious for amazing price swings -- in either direction -- that can happen overnight. So why is that? Why are biotech stocks in particular so volatile? Why do they keep leading the market every year? And what biotech stock might -- repeat, might -- pull off this feat next year? Let's analyze why Axsome, Novavax, and Cassava zoomed higher over the last few years, and why I think Pieris Pharmaceuticals (NASDAQ:PIRS) has a chance at a similar remarkable performance in 2022.\n\nBiotech winners tend to start off tiny\nThe main reason these stocks were able to soar so impressively is that all three started with very tiny market caps. At the end of 2018, Axsome Therapeutics had a micro-cap valuation of $85 million. In 2019, Novavax stock fell to below $1, and the company had to do a 1-for-20 reverse split in order to keep its shares listed on the Nasdaq. And at the beginning of 2020, Cassava had barely achieved small-cap status, with its market cap hovering at $240 million.\nSo all three barn-burning stocks started off unloved by the market. Why does a biotech stock get so cheap? Probably the most common reason is the market believes the company's science is bad. Novavax, for instance, had a notable failure in its quest for a respiratory syncytial virus (RSV) vaccine. This clinical trial failure sent investors to the exits and sent the stock down into a crater in 2019, when it plunged to $4 a share (or $0.20 pre-split).\nYet the market was spectacularly wrong about Novavax. While the company's RSV drug was a failure, Novavax had another drug in clinical trials, a flu vaccine. And this drug was a world-beater. It was flying through clinical trials, and it had defeated the market-leading flu vaccines from Sanofi SA (NASDAQ:SNY) over and over again.\nIn 2019, Novavax had the label of \"bad science,\" but the data for a different drug said otherwise. Sometimes companies with tiny market caps actually have compelling drugs that are performing exceptionally well in clinical trials. If you find such a company, you might want to buy some shares.\nIs there enough money for a phase 3 trial?\nThat said, it's not enough just to have good science. Nobody is allowed to market their drugs to the public until that science has been validated in clinical trials and approved by the U.S. Food and Drug Administration -- and clinical trials cost a huge amount of money. Thus, before investing, it's important to determine whether the biotech has enough cash for a phase 3 trial. If the answer is \"no,\" the drug is stalled and won't go anywhere.\nMany unprofitable biotech companies finesse the money issue by collaborating with Big Pharma. When you see such a collaboration, you can have faith that there's enough cash for a phase 3 trial. However, these arrangements also often mean that the bigger pharmaceutical company acquires the rights to the molecule. And that can be like like selling off your future in order to pay the bills today.\nInterestingly, neither Axsome nor Novavax nor Cassava have an active collaboration with any big-pharma leaders. Instead, all three of these companies have elected to own 100% of the rights to their lead molecules. While the median expense for a phase 3 trial is $19 million, the numbers can vary dramatically, depending on how large the patient population is. I'd be nervous if a biotech had less than $100 million in cash (each of these has more). There's no question this independent approach is riskier, but also potentially a lot more rewarding.\nBiotech investors often like to see collaboration with Big Pharma -- it's a validation of the science, and it removes a lot of financial worries for small companies. But if you're chasing big rewards, you might want to look at biotech companies that are still independent (and have enough cash to stay that way).\nCan Pieris pull off a miracle run in 2022?\nPieris stock is very cheap right now, with a $291 million valuation. (You know a stock is cheap when it could have a 10-bagger and still qualify as a small-cap!) Is the stock so cheap because its science is bad?\nIt would probably be more accurate to say that Pieris' science is unproven. Like many unprofitable biotechs, Pieris doesn't have a drug in phase 3 trials yet. In fact, we're still waiting on positive phase 2 data. So it's early, and that's a danger sign. The reason Axsome, Novavax, and Cassava all skyrocketed is that all three companies made the journey from unproven drug to pivotal trials very quickly. Pieris is a few years away.\nAnother major difference is that Pieris has signed multiple collaborative deals -- with Roche, AstraZeneca, and Seagen, among others. In one sense that's good news, because it means that money for clinical trials isn't an issue for the company. Any drugs that work will make it to phase 3 trials and beyond. And all this collaboration adds confidence that the company is on the right track.\nIs Pieris sacrificing its future to pay for its present? In my opinion, no. While AstraZeneca now has rights to the company's asthma drug (its lead molecule), what makes Pieris such an exciting stock is not one particular drug, but the company's entire platform. Pieris owns the rights to all the Anticalin proteins, and its library contains more than 100 billion of these new molecules. Anticalins are much smaller than antibodies, and as such can go where antibodies cannot. AstraZeneca paid big bucks for the rights to Pieris' asthma drug because that Anticalin molecule is small enough to go directly to the lung.\nI love the risk/reward equation for Pieris. If the company's drugs actually work -- we'll have data in that regard next year -- the stock will shoot much higher. Under its existing collaboration agreements, Pieris might make up to $9 billion if its Anticalin drugs reach certain milestones. But what will really make the stock take off is if/when other pharmaceutical players start making deals to add some of the company's Anticalin molecules to their pipelines.\nHow do you value an entire new class of pharmaceuticals? Well, in 2019, worldwide sales for monoclonal antibodies (mAbs) totaled $163 billion. If Pieris' partners report any positive data on its Anticalin drugs next year, the upside for this stock is enormous.","news_type":1},"isVote":1,"tweetType":1,"viewCount":101,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":816936916,"gmtCreate":1630459575735,"gmtModify":1633677911946,"author":{"id":"4087953198586960","authorId":"4087953198586960","name":"Smart74","avatar":"https://static.tigerbbs.com/03a3700aaa7249889bedd5bd5e73f9ae","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087953198586960","authorIdStr":"4087953198586960"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/816936916","repostId":"1116780264","repostType":4,"isVote":1,"tweetType":1,"viewCount":209,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":839252931,"gmtCreate":1629163033923,"gmtModify":1633686922842,"author":{"id":"4087953198586960","authorId":"4087953198586960","name":"Smart74","avatar":"https://static.tigerbbs.com/03a3700aaa7249889bedd5bd5e73f9ae","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087953198586960","authorIdStr":"4087953198586960"},"themes":[],"htmlText":"Great&nbsp;","listText":"Great&nbsp;","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/839252931","repostId":"2160278866","repostType":4,"repost":{"id":"2160278866","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1629153526,"share":"https://www.laohu8.com/m/news/2160278866?lang=&edition=full","pubTime":"2021-08-17 06:38","market":"us","language":"en","title":"S&P 500, Dow hit record highs as defensive shares shine","url":"https://stock-news.laohu8.com/highlight/detail?id=2160278866","media":"Reuters","summary":"* Healthcare sector rises over 1%, utilities, staples gain\n* Cyclical areas off: Energy, materials, ","content":"<p>* Healthcare sector rises over 1%, utilities, staples gain</p>\n<p>* Cyclical areas off: Energy, materials, financials weak</p>\n<p>* China factory output, retail sales growth slow sharply</p>\n<p>* Tesla slumps after U.S. opens probe into Autopilot</p>\n<p>* Dow up 0.31%, S&amp;P up 0.26%, Nasdaq down 0.2%</p>\n<p>Aug 16 (Reuters) - The benchmark S&amp;P 500 and the Dow industrials hit record highs on Monday as investors moved into defensive sectors and stocks recovered from losses earlier in the session, shaking off glum economic data out of China.</p>\n<p>Economically sensitive groups such as energy, materials and financials were weaker after China's factory output and retail sales growth slowed sharply and missed expectations in July, as new COVID-19 outbreaks and floods disrupted business operations.</p>\n<p>But healthcare gained 1.1%, the best-performing S&amp;P 500 sector. Utilities and consumer staples -- also generally regarded as defensive sectors -- further bolstered market gains.</p>\n<p>The S&amp;P 500 and the Dow both posted record high closes for their fifth straight sessions, even after the major indexes were initially well in the red.</p>\n<p>\"There is just huge amounts of liquidity, massive amounts of cash out there, both on corporate balance sheets and in private investors’ pockets, and because of that every tiny dip that there is, people look for bargains and they buy and they keep it buoyant,\" said Randy Frederick, vice president of trading and derivatives for Charles Schwab in Austin, Texas.</p>\n<p>The Dow Jones Industrial Average rose 110.02 points, or 0.31%, to 35,625.4, the S&amp;P 500 gained 11.71 points, or 0.26%, to 4,479.71 and the Nasdaq Composite dropped 29.14 points, or 0.2%, to 14,793.76.</p>\n<p>A rebound in the U.S. economy including a stellar second-quarter corporate earnings season along with accommodative monetary policy has underpinned positive sentiment for equities. The S&amp;P 500 has gained 100% since its March 2020 low.</p>\n<p>“The overall environment remains supportive of risk assets, so there is a gravitational pull upward for stocks,” said Kristina Hooper, chief global market strategist at Invesco.</p>\n<p>Investors are looking for signs about when the Federal Reserve will rein in its easy money policies, with minutes from the central bank's latest meeting due on Wednesday. A resurgence in COVID-19 cases and the impact on the economy are keeping markets on edge, with investors watching earnings reports from major retailers due later in the week.</p>\n<p>Investors were also digesting news from Afghanistan, where thousands of civilians desperate to flee the country thronged Kabul airport after the Taliban seized the capital.</p>\n<p>In company news, Tesla shares fell 4.3% after U.S. auto safety regulators said they had opened a formal safety probe into the company's driver assistance system Autopilot after a series of crashes involving emergency vehicles.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.75-to-1 ratio; on Nasdaq, a 2.22-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 68 new 52-week highs and one new lows; the Nasdaq Composite recorded 72 new highs and 259 new lows.</p>\n<p>About 8.5 billion shares changed hands in U.S. exchanges, below the 9.2 billion daily average over the last 20 sessions.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 500, Dow hit record highs as defensive shares shine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500, Dow hit record highs as defensive shares shine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-17 06:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>* Healthcare sector rises over 1%, utilities, staples gain</p>\n<p>* Cyclical areas off: Energy, materials, financials weak</p>\n<p>* China factory output, retail sales growth slow sharply</p>\n<p>* Tesla slumps after U.S. opens probe into Autopilot</p>\n<p>* Dow up 0.31%, S&amp;P up 0.26%, Nasdaq down 0.2%</p>\n<p>Aug 16 (Reuters) - The benchmark S&amp;P 500 and the Dow industrials hit record highs on Monday as investors moved into defensive sectors and stocks recovered from losses earlier in the session, shaking off glum economic data out of China.</p>\n<p>Economically sensitive groups such as energy, materials and financials were weaker after China's factory output and retail sales growth slowed sharply and missed expectations in July, as new COVID-19 outbreaks and floods disrupted business operations.</p>\n<p>But healthcare gained 1.1%, the best-performing S&amp;P 500 sector. Utilities and consumer staples -- also generally regarded as defensive sectors -- further bolstered market gains.</p>\n<p>The S&amp;P 500 and the Dow both posted record high closes for their fifth straight sessions, even after the major indexes were initially well in the red.</p>\n<p>\"There is just huge amounts of liquidity, massive amounts of cash out there, both on corporate balance sheets and in private investors’ pockets, and because of that every tiny dip that there is, people look for bargains and they buy and they keep it buoyant,\" said Randy Frederick, vice president of trading and derivatives for Charles Schwab in Austin, Texas.</p>\n<p>The Dow Jones Industrial Average rose 110.02 points, or 0.31%, to 35,625.4, the S&amp;P 500 gained 11.71 points, or 0.26%, to 4,479.71 and the Nasdaq Composite dropped 29.14 points, or 0.2%, to 14,793.76.</p>\n<p>A rebound in the U.S. economy including a stellar second-quarter corporate earnings season along with accommodative monetary policy has underpinned positive sentiment for equities. The S&amp;P 500 has gained 100% since its March 2020 low.</p>\n<p>“The overall environment remains supportive of risk assets, so there is a gravitational pull upward for stocks,” said Kristina Hooper, chief global market strategist at Invesco.</p>\n<p>Investors are looking for signs about when the Federal Reserve will rein in its easy money policies, with minutes from the central bank's latest meeting due on Wednesday. A resurgence in COVID-19 cases and the impact on the economy are keeping markets on edge, with investors watching earnings reports from major retailers due later in the week.</p>\n<p>Investors were also digesting news from Afghanistan, where thousands of civilians desperate to flee the country thronged Kabul airport after the Taliban seized the capital.</p>\n<p>In company news, Tesla shares fell 4.3% after U.S. auto safety regulators said they had opened a formal safety probe into the company's driver assistance system Autopilot after a series of crashes involving emergency vehicles.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.75-to-1 ratio; on Nasdaq, a 2.22-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 68 new 52-week highs and one new lows; the Nasdaq Composite recorded 72 new highs and 259 new lows.</p>\n<p>About 8.5 billion shares changed hands in U.S. exchanges, below the 9.2 billion daily average over the last 20 sessions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF",".IXIC":"NASDAQ Composite","SH":"标普500反向ETF","IVV":"标普500指数ETF","TSLA":"特斯拉",".DJI":"道琼斯","SPY":"标普500ETF","UPRO":"三倍做多标普500ETF","OEX":"标普100",".SPX":"S&P 500 Index","SPXU":"三倍做空标普500ETF","SDS":"两倍做空标普500ETF","OEF":"标普100指数ETF-iShares","SSO":"两倍做多标普500ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2160278866","content_text":"* Healthcare sector rises over 1%, utilities, staples gain\n* Cyclical areas off: Energy, materials, financials weak\n* China factory output, retail sales growth slow sharply\n* Tesla slumps after U.S. opens probe into Autopilot\n* Dow up 0.31%, S&P up 0.26%, Nasdaq down 0.2%\nAug 16 (Reuters) - The benchmark S&P 500 and the Dow industrials hit record highs on Monday as investors moved into defensive sectors and stocks recovered from losses earlier in the session, shaking off glum economic data out of China.\nEconomically sensitive groups such as energy, materials and financials were weaker after China's factory output and retail sales growth slowed sharply and missed expectations in July, as new COVID-19 outbreaks and floods disrupted business operations.\nBut healthcare gained 1.1%, the best-performing S&P 500 sector. Utilities and consumer staples -- also generally regarded as defensive sectors -- further bolstered market gains.\nThe S&P 500 and the Dow both posted record high closes for their fifth straight sessions, even after the major indexes were initially well in the red.\n\"There is just huge amounts of liquidity, massive amounts of cash out there, both on corporate balance sheets and in private investors’ pockets, and because of that every tiny dip that there is, people look for bargains and they buy and they keep it buoyant,\" said Randy Frederick, vice president of trading and derivatives for Charles Schwab in Austin, Texas.\nThe Dow Jones Industrial Average rose 110.02 points, or 0.31%, to 35,625.4, the S&P 500 gained 11.71 points, or 0.26%, to 4,479.71 and the Nasdaq Composite dropped 29.14 points, or 0.2%, to 14,793.76.\nA rebound in the U.S. economy including a stellar second-quarter corporate earnings season along with accommodative monetary policy has underpinned positive sentiment for equities. The S&P 500 has gained 100% since its March 2020 low.\n“The overall environment remains supportive of risk assets, so there is a gravitational pull upward for stocks,” said Kristina Hooper, chief global market strategist at Invesco.\nInvestors are looking for signs about when the Federal Reserve will rein in its easy money policies, with minutes from the central bank's latest meeting due on Wednesday. A resurgence in COVID-19 cases and the impact on the economy are keeping markets on edge, with investors watching earnings reports from major retailers due later in the week.\nInvestors were also digesting news from Afghanistan, where thousands of civilians desperate to flee the country thronged Kabul airport after the Taliban seized the capital.\nIn company news, Tesla shares fell 4.3% after U.S. auto safety regulators said they had opened a formal safety probe into the company's driver assistance system Autopilot after a series of crashes involving emergency vehicles.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.75-to-1 ratio; on Nasdaq, a 2.22-to-1 ratio favored decliners.\nThe S&P 500 posted 68 new 52-week highs and one new lows; the Nasdaq Composite recorded 72 new highs and 259 new lows.\nAbout 8.5 billion shares changed hands in U.S. exchanges, below the 9.2 billion daily average over the last 20 sessions.","news_type":1},"isVote":1,"tweetType":1,"viewCount":161,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":891577728,"gmtCreate":1628405644664,"gmtModify":1633747296274,"author":{"id":"4087953198586960","authorId":"4087953198586960","name":"Smart74","avatar":"https://static.tigerbbs.com/03a3700aaa7249889bedd5bd5e73f9ae","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087953198586960","authorIdStr":"4087953198586960"},"themes":[],"htmlText":"Great!","listText":"Great!","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/891577728","repostId":"1190347839","repostType":4,"isVote":1,"tweetType":1,"viewCount":158,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172220717,"gmtCreate":1626963127439,"gmtModify":1633769323601,"author":{"id":"4087953198586960","authorId":"4087953198586960","name":"Smart74","avatar":"https://static.tigerbbs.com/03a3700aaa7249889bedd5bd5e73f9ae","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087953198586960","authorIdStr":"4087953198586960"},"themes":[],"htmlText":"Nice[Smile]&nbsp;","listText":"Nice[Smile]&nbsp;","text":"Nice[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/172220717","repostId":"1175975559","repostType":4,"isVote":1,"tweetType":1,"viewCount":78,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}